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ABSTRACT 
Effects of Estrogen in an Aged Animal Model of Stroke 
Rachel L. León 
 
In 2000, approximately 10 million women were taking hormone replacement therapy (HRT) for 
alleviation of menopausal symptoms. A number of prior animal studies also suggested that HRT 
may be neuroprotective and cardioprotective as well. Although estrogen is neuroprotective in 
young adult animal models of stroke, clinical trials demonstrate that estrogen increases the inci-
dence and severity of stroke in aged women. We have previously shown that experimental 
stroke pathophysiology differs between young adult and aged rats. In the first study, we show 
that aged rats treated with 17!-estradiol had significantly increased infarct volumes compared to 
placebo-treated aged rats. Young adult rats treated with 17!-estradiol had significantly de-
creased infarct volumes and functional outcome compared to ovariectomized young adult rats. 
Aged female rats treated with 17!-estradiol had decreased post-ischemic GFAP-positive astro-
cytes and altered astrocyte morphology. In the second study, we investigate a potential mecha-
nism involved in the deleterious effects of estrogen in the aged female rat brain. In rats chroni-
cally supplemented with estrogen or placebo, we measure a significant reduction in erythropoi-
etin (EPO) receptor mRNA in the ischemic cortex following transient occlusion of the middle 
cerebral artery. We also observe decreased EPO-receptor protein expression in the penumbral 
cortex and striatum using immunohistochemical techniques. In a second group of rats, we con-
firm that EPO administration attenuates estrogen-induced increase in infarct volume, and is ac-
companied by decreased expression of ER" in the ischemic penumbra. In the third study, we 
assess hippocampal-dependent memory using the 8-arm radial maze in young adult and aged 
female rats following middle cerebral artery occlusion with fibrin clot and tissue plasminogen 
activator reperfusion. Aged rats required greater number of sessions to become trained and had 
increased trial duration, suggesting reduced locomotor activity. Although baseline differences in 
reference and working memory errors were observed, they did not reach significance. Following 
MCAO, no significant differences were found in reference or working memory errors between 
young adult and aged rats. Finally, we investigate the effects of estrogen supplementation on 
structure and function of lacrimal and Meibomian glands in aged female rats. Following 90 days 
of estrogen supplementation in aged female rats, a reduction in tear volume and tear break up 
time in estrogen treated rats was accompanied by increased connective tissue fibrosis in both 
extraorbital and intraorbital lacrimal glands and reduced acinar lumen in the intraorbital lacrimal 
glands. These functional and structural changes are likely mediated by ER", as estrogen treat-
ment led to upregulation of ER" expression in lacrimal and Meibomian glands.   
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Chapter One 
 
Literature Review  
Accepted for publication in American Journal of Pathology. 
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ABSTRACT 
In 2000, approximately 10 million women were taking hormone replacement therapy (HRT) for 
alleviation of menopausal symptoms. A number of prior animal studies also suggested that HRT 
may be neuroprotective and cardioprotective as well. Then, in 2003, reports from the Women’s 
Health Initiative (WHI) indicated that chronic estrogen/progestin supplementation led to in-
creased incidence of stroke. A second branch of the WHI in women with prior hysterectomy 
found an even stronger correlation between estrogen supplementation alone and stroke inci-
dence. Follow up analyses of the data, as well as data from other smaller clinical trials, has also 
demonstrated increased stroke severity in women taking HRT or estrogen alone. This review 
examines the studies indicating that estrogen is neuroprotective in animal models and explores 
potential reasons why this may not be true in postmenopausal women. Specifically, age-related 
differences in estrogen receptors and estrogenic actions in the brain are discussed with the 
conclusion that animal models of disease must closely mimic the human pathology in order to 
produce clinically relevant results.  
 
  
3 
Age-related differences in brain injury 
Stroke is the leading cause of long term disability and the third leading cause of death in 
the United States. According to the American Heart Association, approximately 72% of people 
who suffer a stroke are over 65 years old, almost 25% of the population over 75 years old will 
suffer a stroke, and for people over the age of 55 years, the incidence of stroke more than dou-
bles each successive decade (Figure 1.1). Due to the increased incidence of traumatic brain 
injury (TBI) in young adults, young animal models have a role in understanding the mechanisms 
involved in the injured brain, particularly in the traumatically injured brain. However, this review 
argues that young animal models do not accurately represent the response to injury unique to 
the aged brain; thus, aged animals must have a place in the study of neural injury, particularly 
stroke.  
Both basic science (Popa-Wagner et al., 2007) and clinical studies (Marquez de la Plata 
et al., 2008) indicate that older age decreases the ability of the brain to recover from neural inju-
ry. Neural injury causes an initial region of cell death followed by a secondary phase of injury 
characterized by release of intracellular glutamate and calcium, an inflammatory response, acti-
vation of apoptotic pathways, formation of reactive oxygen species (ROS), and blood-brain bar-
rier (BBB) disruption. Animal studies of stroke have shown unique, age-related differences in 
both phases of ischemic injury (Badan et al., 2003b, Baltan et al., 2008). Specifically, aged rats 
have larger infarct volume (Popa-Wagner et al., 2007) and less functional recovery (Badan et 
al., 2003a) than young adult rats after transient focal cerebral ischemia. Morphological changes 
in the brain of aged rats following neural injury include massive infiltration of polymorphonuclear 
neutrophils, pettichiae, and necrosis formation (Rosen et al., 2005). These markers of inflamma-
tion are reduced in the post-ischemic brain of young adult rats (Dinapoli et al., 2006). Clinically, 
age-related differences in functional recovery from neural injury are well established. Results 
from a recent clinical study assessing over 400 TBI victims (ages ranging from 16 to 85 yr and 
divided into three groups: 16-26, 27-39, and 40-85) at one and four years after injury showed 
4 
similar improvements initially between age groups, but vast differences at the five-year assess-
ment (Marquez de la Plata et al., 2008). These findings, along with a number of other investiga-
tions, cite age as a predictive factor in functional outcome from TBI (Flanagan et al., 2005). Old-
er age also leads to greater disability following cerebral ischemia including decreased ability to 
perform activities of daily living, higher percentage of use of assistive devices for ambulation, 
and increased use of institutionalized care facilities (Kelly-Hayes et al., 2003). 
Several hypotheses exist to explain the mechanisms at work in the aging brain: in-
creased inflammation, decreased metabolic reserve, and accumulation of reactive oxygen spe-
cies. The “inflammation hypothesis of aging”, also termed “Inflam-Aging”, suggests that in-
creased inflammation during the aging process results from deregulation of the immune system 
and a progressive inability to handle pathological stimuli (Chung et al., 2001). Aging in the brain 
is characterized by cortical atrophy, and an increased number of activated astrocytes and mi-
croglia (Rosenberg, 2005). Another prominent idea is that aged brains have an accumulation of 
reactive oxygen species along with reductions in the enzymes to control them. Specific genes 
(i.e. age-1, daf-2, methuselah, and shc) have been identified that demonstrate a definitive con-
nection between accumulation of ROS and longevity (Finkel and Holbrook, 2000). Although ag-
ing is a complex process influenced by many factors, the aged brain is clearly unique from its 
younger counterpart in both health and disease.   
 
Animal models of stroke 
Eighty-seven percent of strokes are ischemic in nature, with the most common site of 
occlusion the middle cerebral artery (MCA). For this reason, most stroke models utilize occlu-
sion of the MCA, which results in reduced cerebral blood flow to areas supplied by that artery 
including the lateral surface of the hemisphere, parts of the basal ganglia, and the internal cap-
sule (Ponten et al., 1973, Garcia, 1984). Models of MCA occlusion (MCAO) can be divided into 
two main categories: physical occlusion and chemically-induced occlusion. Methods of physical 
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inclusion include lifting the MCA with a tungsten hook (Badan et al., 2003a) photothrombotic 
occlusion (Yao et al., 2003), or through the use of suture (Liu et al., 2009) or fibrin clot occlusion 
(DiNapoli et al., 2006) inserted into the vessel lumen. Chemical occlusion consists of admin-
istration of endothelin-1 directly onto the exposed vessel which leads to vessel constriction and 
reduced blood flow (Moyanova et al., 2003, Nikolova et al., 2009). Methods of physical occlu-
sion have the benefit of either being permanent (Bederson et al., 1986) or transient (Longa et 
al., 1989, Belayev et al., 1996), while chemical occlusion is always transient. 
The most clinically relevant model of stroke utilizes a fibrin-rich blood clot to create an 
ischemic stroke, followed by tissue plasminogen activator (tPA) administration to disrupt the clot 
and permit re-opening of the vessel for reperfusion of ischemic tissue (Kudo et al., 1982, 
Kaneko et al., 1985, Dinapoli et al., 2006).  While the use of tPA has some caveats, there are 
several advantages in using the fibrin clot model, including smaller, more precise infarctions, a 
mortality more representative of the clinical setting, slower, more clinically relevant reperfusion, 
the ability to utilize thrombolytic therapy, screen for neuroprotectants and develop clinically use-
ful combination therapies. In addition, the use of laser Doppler monitoring of blood ensures 
proper ischemic depth and allows the reperfusion with tPA to be monitored. In addition to using 
a fibrin-rich clot, the use of aged animals plays a crucial role in creating a clinically relevant 
model for stroke research.  
The guidelines for preclinical stroke research have been debated and discussed with ini-
tial recommendations provided by the Stroke Therapy Academic Industry Roundtable (STAIR) 
in 1999 (Fisher et al., 2009). In those guidelines, members of the STAIR group recommended 
that preclinical stroke models study potential stroke therapies in blinded, physiologically con-
trolled experiments with rodents initially. They also recommended that studies create dose re-
sponse curves, evaluate effectiveness in permanent occlusion first, then move to transient oc-
clusion models, and assess functional and histological outcomes both acutely and long term. In 
a 2006 systematic review of nearly 3500 articles published from 1957 until 2003, O’Collins et al. 
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found that only 5 of 550 drugs tested as stroke therapeutics adhered to the STAIR I recommen-
dations (O'Collins et al., 2006). The quality score, based upon level of adherence to STAIR I 
recommendations was inversely correlated with the efficacy of the drug reported, meaning that 
poorer quality studies routinely reported greater efficacy of the study drug than more rigorous 
studies. Recently, the STAIR committee updated their recommendations for preclinical stroke 
research and added additional criteria. First, studies with positive results should be repeated in 
an independent laboratory for validation. STAIR also specifically recommends that following ini-
tial studies in young, healthy animals, studies should be conducted in aged animals and animals 
with comorbidities such as hypertension, diabetes, obesity, and hypercholesterolemia. Other 
criteria include the use of both male and female animals and the use of relevant biomarker end-
points.  
 
Age-related differences in estrogen activity in the brain 
There is substantial evidence that estrogen is an effective neuroprotectant. The second-
ary phase of neural injury activates numerous inflammatory, pro- and anti-apoptotic, and angio-
genic factors. These processes respond to estrogen differentially depending on age. Studies 
performed by a variety of investigators clearly show that estrogen reduces infarct size (Dubal et 
al., 1998), neuronal cell death (Rau et al., 2003), and mortality (Simpkins et al., 1997) following 
neural injury. One common variable in almost all studies showing neuroprotection by estrogen is 
the use of young animals. The few studies that have examined age-related differences in estro-
genic effects have used models of injury that do not mimic stroke or methods of estrogen sup-
plementation that do not mimic its clinical use. One study that investigated age-related differ-
ences in estrogenic actions used a 10-minute period of global ischemia – an injury that mimics 
cardiac arrest, rather than stroke (Wappler et al.). A study concluding that estrogen supplemen-
tation attenuates stroke injury in aged female rats used only one week of estrogen exposure 
before middle cerebral artery occlusion by intraluminal filament (Alkayed et al., 2000). Clinical 
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trials, however, have shown a clear relationship between increased stroke incidence and severi-
ty with estrogen supplementation in postmenopausal women (Wassertheil-Smoller et al., 2003, 
Anderson et al., 2004).  
 
Clinical trials show estrogen increases stroke risk and stroke severity 
The Women’s Health Initiative (WHI) randomized controlled trials investigated the bene-
fits and risks of 0.625 mg/day conjugated equine estrogen (CEE) plus 2.5 mg/day medroxypro-
gesterone acetate (MPA) in 16,608 women. The trials were terminated before the planned end 
date due to elevated breast cancer risk along with other risks defined in the global index as time 
to incident coronary heart disease, stroke, pulmonary embolism, hip fracture, or death from oth-
er causes (Wassertheil-Smoller et al., 2003). The average follow-up of women in the CEE/MPA 
trial was 5.6 years. In that time the CEE/MPA group experienced 151 strokes (1.8%) while the 
placebo-treated group had 107 strokes (1.3%). The hazard ratio (HR) for all stroke subtypes 
was 1.31 (95% CI, 1.02-1.68). For ischemic stroke, however, the HR was 1.44 (95% CI, 1.09-
1.90) indicating an approximate 31% increase in stroke risk with CEE/MPA compared to place-
bo. The elevated risk of stroke with CEE/MPA could not be attributed to any other risk factor and 
did not appear until after the first year of treatment.  
A second branch of the WHI simultaneously studied the effects of CEE alone in 10,739 
women with prior hysterectomy (Anderson et al., 2004). Researchers also found an increased 
risk of ischemic stroke with CEE, warranting the early termination of those trials as well. When 
the CEE trial was stopped, the participants had an average of 6.8 years of follow-up. The HR for 
stroke in those taking CEE vs. placebo was 1.39 (95% CI 1.10-1.77) with an absolute excess 
risk of 12 additional strokes per 10,000 person-years. Although this elevation of stroke risk may 
be associated with an observed increase in systolic blood pressure, there are likely more global 
effects of CEE requiring further investigation.  
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Smaller-scaled clinical trials have shown increased stroke severity with estrogen treat-
ment in women with known vascular disease. The Women’s Estrogen for Stroke Trial (WEST) 
was a randomized, double-blind, placebo-controlled trial of 664 postmenopausal women that 
demonstrated increased risk of fatal stroke and worse neurological outcome from stroke in 
women taking estrogen (17!-estradiol, 1 mg/day) after a first cerebral ischemic event (Viscoli et 
al., 2001). The Heart and Estrogen/progestin Replacement Study (HERS) investigated the use 
of CEE/MPA (0.625 mg/day CEE, 2.5 mg/day MPA) in 2,763 women with coronary heart dis-
ease and found that treatment was not significantly associated with risk of stroke (HR 1.23; 95% 
CI 0.89-1.70), but it also did not reduce the incidence of coronary or cerebrovascular events as 
expected (Hulley et al., 1998). Interestingly, HERS (Grady et al., 2000) as well as the unblinded 
follow-up study (HERSII) did find a significant increase in the risk of thromboembolic events 
(deep vein thrombosis and pulmonary embolism) in women taking HRT compared to those tak-
ing placebo (HR 2.08, 95% CI 1.28-3.40) (Hulley et al., 2002), indicating a possible role of es-
trogen in thrombus creation. Two separate meta-analyses combining data from each of these 
three clinical trials as well as many other smaller trials have shown a clearly increased risk of 
stroke incidence and severity with HRT (Bath and Gray, 2005, Sare et al., 2008).  
 
Timing of initiation hypothesis 
Researchers have responded to these reports by arguing that variations in the timing of 
initiation of estrogen treatment, is the probable reason for differences between animal studies 
and the clinical trial data. They contend that a period of hypoestrogenicity following menopause 
leads to irreversible vascular changes that are not mimicked in ovariectomized animals immedi-
ately supplemented with estrogen. Participants in the WHI trials were between 50 and 79 years 
old with an average age of 63 years – approximately 12 years after the average age of meno-
pause. However, subsequent analyses of WHI data of women with prior CEE and/or CEE/MPA 
use that began within 5 years of menopause has not supported the “timing of initiation hypothe-
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sis” (Prentice et al., 2009). However, basic science research from proponents of the “timing of 
initiation hypothesis” has supported the idea that a period of hypoestrogenicity negates the neu-
roprotection afforded by constant estrogen exposure. In particular, one study examining the 
“timing of initiation hypothesis” showed a significant difference between infarct volumes of mice 
supplemented with estrogen immediately following ovariectomy and a placebo-treated control 
group. A second comparison was made between mice undergoing a 10-week period of no es-
trogen exposure compared to a second control group, showing no significant differences in in-
farct volumes (Suzuki et al., 2007). The key comparison, however, was not presented in that 
study – namely, differences in infarct volumes between mice immediately supplemented with 
estrogen and those undergoing a period of hypoestrogenicity. By comparing each treatment 
group to a control (placebo-treated) group rather than to each other, no conclusions regarding 
the “timing of initiation hypothesis” can be made. Furthermore, these studies, among others, 
utilizing young animals cannot be used to predict the role estrogen plays in the aged brain. 
 
Age, not timing, determines response to estrogen 
Age is the likely variable accounting for the contrast between animal studies and clinical 
trial findings. The vast majority of basic science studies in neural injury, including studies on the 
effects of estrogen, utilize young animals. This research is based on the assumption that aging 
is a linear process, whereas studies on aging do not support that claim (Bishop et al.) Therefore, 
assessment of the response to neural injury in young or middle-aged rats cannot be used to ex-
trapolate data to predict a post-injury response in an aged animal or, more importantly, in an 
aged patient. Together, these factors indicate that more studies on estrogenic effects on stroke, 
using clinically relevant animal models, are warranted. Evidence presented in this review sug-
gests that estrogenic down regulation of the post-ischemic inflammatory response may contrib-
ute to worsened stroke injury by attenuating beneficial downstream anti-apoptotic and angiogen-
ic pathway activation, which will be discussed more fully. 
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Estrogen receptors within the CNS 
Estrogen mediates many of its actions in the periphery via two forms of the estrogen re-
ceptor (ER), ER" and ER!, encoded on chromosomes six and fourteen, respectively. There are 
at least three known ER" isoforms and five known ER! isoforms, with varying degrees of trans-
activation function (Ishunina et al., 2005). Some ER agonists bind preferentially to one form of 
the ER. Estrone binds with greater affinity to ER", while estriol and reloxifene preferentially bind 
ER!. 17!-estradiol binds equally well to both forms of the ER, thus is used as the most common 
form of estrogen supplementation in research. Upon activation, these receptors act as ligand-
dependent transcription factors by either binding directly to estrogen response elements on tar-
get DNA sequences or by interacting with nuclear proteins to alter gene expression. Estrogen-
induced genomic actions are well understood and occur over hours or days (McDonnell and 
Norris, 2002).  
Neuroprotection by estrogen in young animals is thought to be partially mediated 
through ER"-dependent activity. ER" and ER! are constitutively expressed in cortical (Mannella 
and Brinton, 2006) and hippocampal (Mehra et al., 2005) neurons in addition to cells in many 
other brain regions, yet only ER" is upregulated in astrocytes and microglia following injury 
(Garcia-Ovejero et al., 2002). Estrogen-induced neuronal sparing from ischemia is abolished in 
ER"  knockout mice compared to exacerbated infarcts in ER! knockout mice (Dubal et al., 
2001). However, studies utilizing both the ER" and ER! knockout mice are likely confounded by 
the fact that ER! knockout mice have been shown to be in a state of systemic hypoxia (Morani 
et al., 2006). ER! is highly expressed in type I and type II pneumocytes and the deletion of this 
gene leads to fewer alveoli (Patrone et al., 2003) and reduced lung volume (Massaro and Mas-
saro, 2006). In treadmill tests, ER! knockout mice are highly susceptible to ischemic injury 
compared with wild-type littermates (Morani et al., 2006), thus making this transgenic model 
less than ideal for the study of cerebral ischemia.  
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A G-protein coupled estrogen receptor (GPR30) has also been found, and cited as the 
possible mediator of rapidly occurring, nongenomic estrogenic action (Revankar et al., 2005). 
Specifically, estrogen has been shown to directly stimulate calcium mobilization, activate cAMP-
mediated signaling, and extracellular signal-regulated kinase 1/2 (ERK1/2) activity in multiple 
cell types (Prossnitz et al., 2008). However, debate still exists regarding the role of GPR30. One 
study found that the receptor was not activated by radioactive estradiol nor did estradiol expo-
sure lead to elevations in intracellular cAMP or calcium levels (Otto et al., 2008). Another hy-
pothesis is that rapidly occurring, nongenomic actions of estrogen are mediated through mem-
brane-bound ER. Some reports have shown evidence for an association between a membrane-
bound ER and insulin-like growth factor I (IGF-I) receptors. Colocalization studies indicate that 
IGF-I is present in neurons expressing ER" and in neurons expressing ER! in hypothalamus, 
hippocampus, and cerebral cortex (Cardona-Gomez et al., 2000). Although these studies pro-
vide important information on ER-independent activity, to date a complete understanding of the 
mechanisms of estrogenic effects on the brain are still unclear, and warrant further investigation.   
 
Estrogen receptors differ in the aged brain 
Evidence of a differential effect of estrogen with age has been demonstrated in the brain 
as well as other tissues. Animal models show decreased nuclear ER concentrations in selected 
brain regions of middle-aged rats compared with young adult counterparts (Wise et al., 1984). 
Further investigation has shown differential response to estrogen supplementation with age in 
hypothalamus and pituitary, although it is unknown if the same age-related changes occur in 
other brain regions. Specifically, ovariectomized, young animals supplemented with estrogen 
showed increased ER expression, while middle-aged and aged animals had little or no increase 
in ER in cytosolic or nuclear fractions of hypothalamus and pituitary, despite similar increments 
in plasma estrogen levels in all age groups (Belisle et al., 1985).  
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More recently, post-mortem analysis of specific human brain regions has demonstrated 
age-related changes in levels of a certain ER" splice variant known as mamillary body, exon 1 
(MB1) (Ishunina and Swaab, 2008). Discovered in 2005, this receptor protein variant lacks exon 
1, giving it an expected four-fold decrease in transactivation function, which would alter its re-
sponse to estrogen (Ishunina et al., 2005). Similarly, aging has been associated with reduced 
expression and activity of ER"-transactivation domain interacting protein, metastasis associated 
protein 1 (MTA1), an important regulator of histone deacetylation and transcriptional control 
(Thakur and Ghosh, 2009). These findings suggest that the aged brain may respond differently 
to circulating estrogen (Table 1.1). Although these studies do not provide a complete under-
standing of age-related differences in estrogenic activity in the brain, emerging evidence sup-
ports the idea that estrogen has differential effects depending on age in both health and follow-
ing neurologic insult. 
 
Estrogen produced endogenously by aromatase 
Local production of estrogen by aromatase may play an important role in recovery from 
neural injury, particularly in postmenopausal females and males. Aromatase is a cytochrome 
P450 enzyme that converts testosterone to estradiol and androstenedione to estrone, and pro-
vides the only source of estrogen in males. Aromatase is bound to the endoplasmic reticulum 
and under physiological conditions is expressed at low levels in the brain after the perinatal pe-
riod (Tsuruo et al., 1994). Studies have shown the presence of aromatase in both neurons (Ce-
lotti et al., 1992) and, following insult, in glia (Saldanha et al., 2005). Testosterone, administered 
before or immediately after penetrating brain lesion, has been shown to decrease expression of 
vimentin immunoreactive astrocytes in male orchidectomized rats (Barreto et al., 2007); howev-
er, this effect is likely due to a local conversion of testosterone to estrogen by aromatase. Both 
in vitro (Liu et al., 2008) and in vivo (McCullough et al., 2003) studies with male aromatase 
knockout mice and cell cultures from these transgenic animals, show greater cell death from 
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experimental neural injury compared to wild type counterparts. These reports suggest a signifi-
cant role for the endogenously produced estrogen that arises in response to neural injury. Lev-
els and activity of neural aromatase have not been reported in aged animals. 
 
Estrogen reduces inflammation  
Neuropoietic cytokines and the JAK/STAT pathway 
Inflammation contributes to neural damage in ischemic injury models. Injury leads to in-
creased nuclear factor #B (NF#B) activation, which causes induction of many mediators of in-
flammation. TBI causes elevation of interleukin (IL)-6, IL-1!, and tumor necrosis factor-" (TNF-
"). IL-1 is also a key component of the inflammatory response to neural injury and has been 
shown to cause neuronal cell death (Basu et al., 2004). IL-1 receptor-1 null mice subjected to 
neural injury demonstrate decreased edema, leukocyte infiltration, and overall cell death as well 
as decreased astrocytic reactivity (Lin et al., 2006), indicating that IL-1 receptor activation may 
be detrimental to recovery from neural injury. 
Yet, not all inflammatory factors have adverse effects. In some types of neural injury, 
such as cerebral ischemia, the inflammatory response contributes to the induction of genes that 
aid in microvessel regrowth and the salvage of cells through activation of anti-apoptotic path-
ways (Dziennis et al., 2007). Specifically, IL-6 and other neuropoietic cytokines act on type I cy-
tokine receptors, composed of a ligand-binding domain, CD126, and a signal-transducing do-
main, glycoprotein 130 (gp130).  Intracellular regions of the transmembrane gp130 molecule are 
coupled to the Janus kinase (JAK)/signaling transducer and activator of transcription (STAT) 
pathway – most notably STAT3 (Hirano et al., 2000). STAT3 is activated by phosphorylation on 
a tyrosine residue on its C terminus. Upon phosphorylation, STAT3 forms a hetero- or homodi-
mer and translocates to the nucleus, where it activates transcription of target genes, including 
proteins that are involved in cell survival and proliferation, such as bcl-2, bcl-xL, mcl-1, Fas, sur-
vivin, cyclin D1, cyclin E1, and p21 (Hodge et al., 2005). In addition, other transcription factors, 
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including c-myc, c-jun, and c-fos, are STAT3 targets (Yang et al., 2003). Vascular endothelial 
growth factor and brain derived neurotrophic factor have also been shown to be targets of 
STAT3 and contribute to angiogenesis (Xu et al., 2005).  
Interleukin-6 signaling pathways, specifically JAK2/STAT3, play a major role in modulat-
ing the complex relationship between aging and pathology. Research demonstrates that not all 
actions mediated by IL-6 are beneficial. Elevated CNS levels of IL-6 leads to increased astro-
gliosis and BBB permeability and IL-6 activation of the JAK2/STAT3 pathway contributes to neu-
ronal loss after transient focal cerebral ischemia (Satriotomo et al., 2006). Data from our lab in-
dicate that dysfunction of the JAK2/STAT3 pathway plays a significant role in the increased inju-
ry and decreased functional recovery observed in studies of ischemic injury in aged animals. 
Specifically, during the acute phase after injury, JAK2/STAT3 signaling contributes to a robust 
pro-inflammatory response that leads to an early, more severe BBB disruption. As the injury re-
sponse continues, JAK2/STAT3 signaling is attenuated by desensitization or increased negative 
regulation by the suppressor of cytokine signaling 3 (SOCS3) resulting in decreased angiogen-
esis and increased apoptosis (DiNapoli et al.). Data from clinical studies confirm that elevated 
plasma IL-6 is predictive of greater stroke severity and worsened functional outcome in older 
adults (Nakase et al., 2008) indicating a connection between the inflammatory response, stroke 
severity, and aging. However, studies on aging show that STAT3 expression is decreased in the 
rodent brain with increasing age. The counterpart of STAT3, known as STAT1, is associated 
with detrimental effects following neural injury, and remains unchanged with age (De-Fraja et 
al., 2000). Studies have shown that estrogen increases activation of STAT3 in young adult rats 
after ischemic injury (Dziennis et al., 2007), but it is unknown if this occurs in aged rats following 
neural insult. Other studies indicate that estrogen also increases inhibitors of the JAK2/STAT3 
pathway (Wong et al., 2003). Figure 1.2 indicates known effects of estrogen on gp130 signaling 
through JAK2/STAT3 pathway. It is unknown what the ultimate results of estrogenic actions are 
on STAT3 activation in aged animals following neural injury. 
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Other neuropoietic cytokines also utilize gp130 and activate STAT3. Leukemia inhibitory 
factor (LIF) and oncostatin M (OsM) are two neuropoietic cytokines of particular interest in the 
injured brain. LIF has a myriad of actions throughout the body including enhancing migration of 
inflammatory cells to damaged neuronal tissue (Sugiura et al., 2000). During mammary gland 
involution, LIF induces expression of the two phosphatidylinositol-3-kinase (PI3K) regulatory 
subunits p50 and p55 via STAT3, resulting in diminished levels of Akt activity and eventually 
leading to apoptosis (Abell et al., 2005). OsM reduces excitotoxic damage like that which occurs 
in the peri-infarct region following ischemia/reperfusion injury (Weiss et al., 2006) and activates 
STAT3 to induce apoptosis and cell cycle arrest in certain tumor cells. Data from our lab sug-
gest that aged rats have a more robust post-ischemic increase in LIF, OsM and SOCS3 com-
pared to young adult rats, indicating a potential role of these neuropoietic cytokines and 
SOCS3-mediated inhibition of STAT3 in the worsened recovery from experimental stroke ob-
served in aged animals (DiNapoli et al.).  
 
Estrogen attenuates inflammation in vivo and in vitro  
Estrogen plays a significant role in regulation of inflammatory pathways (Maggi et al., 
2004). In young animals treated with estrogen prior to middle cerebral artery occlusion (MCAO), 
there are reductions in IL-6 and monocyte chemoattractant protein-1 (MCP-1) (Suzuki et al., 
2007).  Further evidence of estrogen-mediated attenuation of neuroinflammation indicates spe-
cific estrogenic effects on microglia following exposure to lipopolysaccharide (LPS) in female 
ovariectomized rats (Vegeto et al., 2006).  It is unknown if such a reduction in microglia reactivi-
ty occurs in aged animals following neural injury. The anti-inflammatory action of estrogen is 
also supported in cell culture models of neural injury. Primary rat microglia cell lines exposed to 
LPS show reduced microglial superoxide release and phagocytic activity when pre-treated with 
estrogen. These effects are abolished by both ER inhibitor and mitogen-activated protein kinase 
(MAPK) inhibitor (Bruce-Keller et al., 2000).  However, no effect is seen in NF#B levels, sug-
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gesting that estrogen-induced anti-inflammatory actions in microglia are likely dependent on ER-
mediated activation of MAPK. MAPK promotes cell survival through cAMP response element 
binding protein (CREB) transcription pathways.  
Therefore, the ability of estrogen to attenuate inflammation may only occur in young an-
imals, or may occur to a lesser extent or by different mechanisms in aged animals. In aged 
brains, the inflammatory response may serve a vital purpose that becomes weakened by anti-
inflammatory activity of estrogen. Following ischemic injury, gp130-mediated upregulation of 
angiogenic and anti-apoptotic factors serves to protect the peri-infarct region from cell death and 
aid in regrowth of microvessels to the damaged area. If these processes are inhibited by estro-
gen in aged animals, perhaps due to differential expression of ER" splice variants and their re-
sponsiveness to circulating estrogen, then exacerbated injury may result. Further research is 
needed to fully characterize the role estrogen plays in the inflammatory response following neu-
ral injury in the aged brain.  
 
Estrogen attenuates reactive gliosis 
Reactive astrocytes undergo gliosis following neural injury, which involves a continuum 
of specific molecular and morphological changes. Transformation of astrocytes to reactive phe-
notype is characterized by increased expression of glial fibrillary acidic protein (GFAP) and vi-
mentin (Stoll et al., 1998). Increased expression of GFAP protein and mRNA is well document-
ed following cerebral ischemia (Petito et al., 1990, Petito and Halaby, 1993).  In patient studies 
of ischemic stroke, there is severe reactive astrogliosis accompanied by proliferation of astro-
cytes forming a glial scar at the infarct border. Quantitative and qualitative analysis has shown 
GFAP expression to be a biomarker of neuronal injury, which is both sensitive and specific 
(O'Callaghan and Sriram, 2005). Induction of GFAP in reactive astrocytes following MCAO pro-
vides a powerful tool in assessing glial reaction to ischemic injury.  
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 Basal levels of GFAP mRNA and protein are elevated in both the human and rodent 
brain with increased age. Constitutive expression of GFAP mRNA is increased in 24 month old 
rodents, as well as in humans age 60-79, in the hippocampus, frontal and temporal cortices 
(Nichols et al., 1993).  GFAP protein has been shown to be elevated in all brain regions, and is 
associated with an age-linked increase in the number hypertrophic astrocytes related to accu-
mulation of glial filaments (Scheff et al., 1980, Hansen et al., 1987, O'Callaghan and Miller, 
1991). Evidence also exists for increased levels of neurofilament protein and gene expression in 
aged animals following transient focal ischemia (Schroeder et al., 2003). Glial activity is aug-
mented in the aging brain. Time course of astroglial and microglial activation, as well as glial 
scarring is abnormally accelerated in normal aged rodents (Badan et al., 2003b). This irregular 
activity has correlated to impairment in functional recovery following MCAO. The expression of 
neurofilament (GFAP) mRNA and protein has been shown to be decreased in the pneumbra of 
aged animals compared to young adults following MCAO. Although some evidence suggests 
that glial scar formation serves to limit and contain post-ischemic neuronal death, gliosis has 
also been shown to inhibit axonal regeneration and remyelination thereby hindering recovery 
from injury (Rosen et al., 1989). Likewise, astrocytes release a host of pro-inflammatory cyto-
kines that may contribute to neuronal damage.  
Estrogen may also exert effects on astrocytes and their response to neural injury. Stud-
ies have shown that astrocytes express both nuclear ER as well as membrane-associated ER 
(Kuo et al., 2009). Several in vivo models of neural injury, including penetrating brain lesion, ex-
citotoxic-induced neurodegeneration, and cholinergic basal forebrain lesion demonstrate estro-
gen-mediated reduction in GFAP and vimentin expression, indicating estrogenic attenuation of 
post-injury activation of astrocytes (Garcia-Ovejero et al., 2002, Djebaili et al., 2005). This activi-
ty appears to be preserved with age, as chronic estrogen treatment also attenuates age-related 
astrocyte activation in hippocampus of 20-month old mice (Lei et al., 2003).  
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Estrogenic effects on microglia 
Microglia comprise between 5% and 15% of all brain cells. Their role is primarily immu-
nologic as evidenced by their macrophage-like properties. The actions of microglia were first 
described by del Rio Hortega in 1932 in experiments involving brain injury. In those studies, del 
Rio Hortega described microglia migration to the site of injury, morphologic changes, prolifera-
tion and phagocytic activity (del Rio-Hortega, 1993). In homeostasis, microglia exhibit a ramified 
morphology, while in reaction to injury they become ameboid often containing phagocytosed 
cellular debri (Giulian and Baker, 1986, Lin et al., 1998). Ramified microglia act in surveillance 
fashion, continuously sampling the extracellular microenvironment (Kreutzberg, 1996). The role 
of microglia in ischemia is multifaceted (Lees, 1993). Microglia activation is initiated within 
minutes following ischemic onset noted by the expression of distinct cell surface molecules, no-
tably MHC-I and MHC-II. Following ischemia, microglia release cytokines, chemokines and oth-
er neurotoxic agents, which are thought to exacerbate neuronal injury and instigate inflamma-
tion. Specifically, the cytokines IL-1, MCP-1 and TGF!-1 are released following ischemic 
(Gehrmann et al., 1992, Banati and Kreutzberg, 1993, Gehrmann et al., 1995). Expression of 
MCP-1 in microglia seems to be a sensitive and early response to CNS insult, even in the ab-
sence of elevated cytokines (Little et al., 2002). Microglia expression of MCP-1 peaks at around 
2 weeks following ischemia, coinciding with peak astrocytosis (Lin et al., 1998). 
Cytokines and chemokines released by microglia, including MCP-1 have been shown to  
regulate, at least in part, astroglial scarring and can impede re-establishment of neuronal axons 
and synapses. Some studies suggest that suppression of microglia improves recovery from cer-
ebral ischemia (Giulian and Baker, 1985). However, evidence also exists for a neuroprotective 
role of microglia. They also participate in release of beneficial growth factors and are responsi-
ble for scavenging cellular debris (O'Callaghan and Sriram, 2005). Microglial expression of os-
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teopontin by microglia occurs at approximately 24 hours following ischemia and has been 
thought to define the peri-infarct region. This new glial-pial boundary may play a role in healing 
of the brain, perhaps through limiting spread of excitotoxic glutamate released from dying cells 
(Ellison et al., 1998). Microglial response to stroke is accelerated in aged animals. The microglia 
response in aged animals at 24 hours correlates well to that seen in young adult animals as late 
as 2 to 4 weeks following insult (Badan et al., 2003b).  
 Estrogenic effects on microglia have been documented in health and disease. Estrogen 
has been shown to inhibit microglia proliferation in vitro. Microglial cell cultures treated with es-
trogen also have reduced basal levels of TNF-" and reduced TNF-" following exposure to LPS 
(Dimayuga et al., 2005). However, in animal models using N-methyl-D-aspartic acid (NMDA)-
induced cytotoxic injury, the effects on IL-1! expression are dependent on age and hormonal 
status (Nordell et al., 2003). The same inhibitory effect of estrogen has been found in animals 
administered LPS intracerebroventricularly (Vegeto E, Belcredito S 2003). Evidence is accumu-
lating that this anti-inflammatory effect of estrogen is mediated through ER". Specifically, ER" 
activation by E2 has been shown to inhibit the transport of nuclear factor #B to the nucleus 
where it acts as a transcription factor of genes involved in the inflammatory response.  
 
Estrogen affects the blood-brain barrier 
The BBB is a functional element of the ‘neurovascular unit,’ an extensive network com-
prised of endothelium, glia, pericytes, neurons, and extracellular matrix. The BBB partitions the 
systemic circulation from brain parenchyma and serves to establish, maintain, and regulate dis-
crete microenvironments within the brain for optimal neuronal function (Huber et al., 2001). The 
neurovascular unit undergoes a number of morphological and functional changes during the ag-
ing process that make the BBB more vulnerable to insult (DiNapoli et al., 2008).  
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Following injury, there are two principle mechanisms by which brain edema develops: 
cytotoxic and vasogenic. Cytotoxic edema results from a loss of ionic homeostasis and can oc-
cur as astrocytes increase glutamate uptake in an attempt to limit excitotoxicity, which requires 
glucose utilization and leads to intracellular water and sodium accumulation. Neurons can un-
dergo cytotoxic swelling when ionic exchangers dysfunction or as part of the metabolic conse-
quences of excitotoxicity. Vasogenic edema occurs when there is a breakdown in the tight junc-
tions between the endothelial cells of the BBB or upregulation of water transport channels in 
perivascular cells, allowing fluid to enter the brain parenchyma. While relatively little is known 
about the specific mechanisms by which estrogen attenuates post-injury edema, evidence sug-
gests it inhibits BBB breakdown following neural insult (Cipolla et al., 2009). 
 
Estrogen inhibits post-injury edema via multiple mechanisms 
Some evidence suggests that estrogen-mediated attenuation of BBB breakdown may be 
related to inhibition of matrix metalloproteinases (MMPs), the enzymes responsible for extracel-
lular matrix remodeling (Liu et al., 2005). Although the effects of estrogen on the family of MMPs 
have long been studied in regards to reproductive physiology as well as pathologies of the en-
dometrium, recent research has focused on the effects of estrogen on centrally located MMPs, 
particularly in relation to BBB disruption. This research has led to potential mechanisms by 
which estrogen helps maintain functional integrity of the BBB following insult. In particular, es-
trogen has been shown to significantly decrease Evans blue extravasation into the brain (Liu et 
al., 2005), a common assay for assessment of BBB disruption. Evans blue complexes to albu-
min making it a 68kDa marker, the passage of which through the BBB indicates marked disrup-
tion. More subtle changes are better assayed with dextrans (10-60kDa), inulin (5kDa), or sodi-
um fluorescein (376 Da), but the effects of estrogen on BBB permeability to those markers has 
not been measured to date. Estrogen also decreases local MMP2 and MMP9 activity following 
ischemia/reperfusion injury (Liu et al., 2005). By inhibiting the enzymes responsible for injury-
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induced BBB breakdown, estrogen indirectly preserves BBB integrity. Several reports have also 
indicated that estrogen can modulate injury-induced ROS generation (Behl et al., 1997, 
Culmsee et al., 1999), which may contribute to the maintenance of BBB functional integrity fol-
lowing insult. Since ROS contribute to BBB breakdown through lipid membrane peroxidation, 
attenuation of ROS production should protect BBB integrity. F(2)-isoprostanes result from free 
radical oxidation of arachidonic acid and are lower in cerebrospinal fluid from female patients 
with severe TBI than in male counterparts (Bayir et al., 2004), thus, antioxidant activity may ac-
count for estrogen-mediated protection of the BBB. Estrogen decreases ROS-related cell death 
through a nongenomic mechanism of action in organotypic hippocampal slice cultures (Behl et 
al., 1997).  Alternatively, this BBB-sparing effect may be attributable to antioxidant capacity of 
progesterone, which decreases F(2)-isoprostanes in vitro (Roof et al., 1997).  
In addition to the mechanisms by which estrogen inhibits BBB disruption, the hormone is 
also involved in formation and clearance of the subsequent edema, through its regulation of the 
major water transport channel in the brain, aquaporin 4 (AQP4). In LPS-induced BBB disruption 
models, estrogen attenuates the induction of AQP4 in perivascular glial cell processes, thereby 
decreasing the associated edema (Tomas-Camardiel et al., 2005). Together, these studies 
demonstrate that estrogen has potential use in the acute treatment of neural injury. Some stud-
ies on estrogenic neuroprotection in young animal models have used acute treatment after neu-
ral insult and found promising results (Liu et al., 2005, Lebesgue et al., 2009). In terms of treat-
ment for stroke, however, aged animal models must also have a place in validating these re-
sults.  
 
Estrogen receptors in cerebral vasculature 
Following TBI, signs of post-injury neuronal hypoxia, including hypoperfusion and jugular 
venous desaturation have been observed. Estrogen may have a role in reducing injury-induced 
hypoxia through actions on cerebral vasculature, as the vasorelaxing property of estrogen has 
22 
been demonstrated. Middle cerebral arteries isolated from female ovariectomized rats supple-
mented with estrogen show greater increase in diameter in response to elevated transmural 
pressure compared to untreated and male rats; yet, differences in vascular responsiveness be-
tween groups are abolished by removal of the vascular endothelium or by inhibition of both nitric 
oxide synthase (NOS) and cyclooxygenase (Geary et al., 2000). These studies and others sug-
gest that activation of ER" leads to cyclooxygenase-1 (COX-1) induction of prostacyclin (Geary 
et al., 2000) and enhanced nitric oxide (NO) synthesis in cerebral vasculature (Stirone et al., 
2005a) (Figure 1.3). Cerebral blood vessels isolated from estrogen-treated rats have increased 
COX-1, prostacyclin synthase and prostacyclin expression (Ospina et al., 2002). Prostacyclin is 
a prostanoid product of COX-1 that acts on both platelets and endothelial cells and activates the 
protein kinase A pathway, resulting in smooth muscle relaxation and subsequent vasodilation.  
Estrogen-treated animals also show elevated levels of endothelial-derived NOS (eNOS) 
mRNA and protein suggesting a role for eNOS-dependent vasodilation (Stirone et al., 2003). 
This mechanism of estrogen-mediated vasodilation is further supported by studies using mouse 
cerebral arteries that demonstrate a reversal of estrogen-mediated changes in vascular tone 
when eNOS is inhibited (Geary et al., 2000) (Figure 1.3). Similar results are found in cultured 
cerebral vessels, where eNOS levels are significantly depressed by ER antagonist treatment 
(McNeill et al., 2002). Modulation in local eNOS levels may be the predominant vascular effect 
of estrogen. Evidence from eNOS knockout mice show elevated COX-1 and prostacyclin com-
pared to control, estrogen-treated animals, although the vascular responses in both groups are 
similar (Li et al., 2004). However, in studies using young adult female rats, ER" immunoreactivi-
ty is not only present in vascular smooth muscle cells; rather, ER" immunoreactivity is also 
found in the nucleus, mitochondria and on the membrane of endothelial cells (Stirone et al., 
2005b). Any potential differences in the effects of estrogen on cerebral blood vessels in the 
aged brain have not been elucidated, but may be an interesting area for future investigation due 
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to the vasogenic actions of estrogen and the known age-related changes in cerebral vascula-
ture.  
 
Effects of estrogen on excitotoxicity 
Most data regarding the effects of estrogen on excitotoxicity rely on cell culture models. 
Evidence from these models suggest that estrogen affects the extent of excitotoxic cell death by 
modulating glutamate-induced cellular influx of calcium (Ciriza et al., 2004, Numakawa et al., 
2007). Research demonstrates that estrogen acts directly on NMDA receptors to enhance ex-
citatory amino acid activity (Smith, 1989). which would enhance glutamate toxicity; however, in 
cultured hippocampal neurons, estrogen can decrease excitoxicity (Goodman et al., 1996). Oth-
er evidence indicates that estrogen down-regulates ionotropic glutamate receptor subunits in 
neurons, which would attenuate the effects of excess extracellular glutamate like that which oc-
curs following neural injury (Numakawa et al., 2007). Estrogen also acts to increase glutamate 
uptake by astrocytes, thus limiting excitotoxic insult to neurons (Liang et al., 2002), although this 
effect was observed in cultured human astrocytes of Alzheimer’s disease patients, so it is un-
known if the same response to estrogen would occur in acute neural injury. Together, these 
studies suggest that estrogenic inhibition ofexcitotoxicity does not play a key role in its post-
injury actions. 
 
Estrogen modulates apoptotic signaling pathways 
Following direct, excitotoxic, oxidative, or hypoxic injury, cells in the brain parenchyma 
may undergo apoptosis or necrosis. Research has shown that estrogen inhibits apoptotic cell 
death following neural injury in young animal models. Specifically, estrogen activates MAPK by 
triggering calcium influx through L-type calcium channels (Cheng et al., 2001) and increases 
levels of activated bcl-2 present in the nucleus of neurons in the peri-ischemic area of young 
adult rats subjected to focal cerebral ischemia (Dziennis et al., 2007). Further evidence of neu-
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ronal sparing by estrogen comes from immortalized hippocampal cell lines, which show rapid 
estrogen-induced CREB phosphorylation that is blocked by both ER inhibitors and MAPK inhibi-
tors (Wade and Dorsa, 2003).  
Estrogen also modulates levels of IGF-1 (Cheng et al., 2001), which is a potent activator 
of the Akt signaling pathway. Akt inhibits apoptosis by inactivating pro-apoptotic proteins such 
as bcl-xl/bcl-2-associated death promoter (BAD) and activating NF#B for transcription of surviv-
al-promoting genes. Studies demonstrate estrogenic activation of Akt and the family of MAPK 
known as ERK1/2 independent of IGF-1 signaling (Mannella and Brinton, 2006), although estro-
gen-mediated increases in IGF-1 may bolster this response. Furthermore, estrogen activates 
the PI3K signaling cascade through an ER-mediated binding with PI3K regulator, p85 (Mannella 
and Brinton, 2006). The interaction between ER and p85 leads to activation of both Akt and 
ERK1/2 in cortical neurons in a time-dependent manner (Mannella and Brinton, 2006). Overall, 
estrogenic effects on apoptotic pathways are complex, a complete understanding of which has 
yet to be elucidated. 
 
Estrogen and the erythropoietin/erythropoietin-receptor system 
Like estrogen, the role of erythropoietin (EPO) was thought to be neuroprotective, which 
was supported by numerous studies in animal models of several types of neural injury (Ber-
naudin et al., 1999, Genc et al., 2004, Zhang et al., 2006a, Gonzalez et al., 2007, Xiong et al., 
2009). Initial small-scale clinical trials of EPO for the treatment of acute stroke seemed promis-
ing (Ehrenreich et al., 2002). Then, in 2009, EPO was used in a larger clinical trial and EPO 
treatment was not associated with favorable outcome. In fact, patients receiving EPO had a sig-
nificantly higher death rate compared to those receiving placebo  (Ehrenreich et al., 2009). Es-
trogen is a known modulator of both EPO and its receptor, and the interaction between these 
two systems may have an important role in the effects of estrogen in the brain. As the mecha-
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nism of estrogenic action in the brain remains unclear, estrogenic effects on the EPO/EPO-R 
system is a prime candidate for further investigation. 
EPO is a glycoprotein well known for its affects on erythropoiesis. The EPO gene is en-
coded on chromosome 7 and consists of five exons and four introns. EPO protein is a 165-
amino acid peptide with four glycosylation sites, which serve to regulate the biological half-life in 
the blood. Its biological activity also relies on two disulfide bonds between cysteine residues 
(Chong et al., 2002). EPO is primarily produced by the peritubular capillary endothelial cells of 
the kidney; however, some production comes from the liver as well, with a larger contribution 
from the liver during fetal development. Previously, the actions of EPO were thought to be lim-
ited to erythroid progenitor cells where it binds to surface receptors (EPO-R) and acts to inhibit 
apoptosis. The intracellular cascades involved in the effects of EPO on erythroid progenitor cells 
include Janus kinase 2 (JAK2)/signal transducer and activator of transcription 5 (STAT5), 
Akt/NF#B, and Ras. The overall effect of EPO is to inhibit caspase-induced apoptosis (Somer-
vaille et al., 2001). The EPO/EPO-R system has been shown to be vital to life as EPO-R knock-
out mice and EPO knockout mice both die in utero due to severe anemia (Lin et al., 1996). The 
timing of EPO-R expression in erythropoiesis is very specific and decreases as erythroid cells 
mature. In recent years, the presence of EPO and EPO-R in other organ systems has been ex-
plored.  
 
EPO and its receptor in the brain  
Evidence is now accumulating for additional actions of EPO within other organ systems 
including the central nervous system. EPO and EPO-R mRNA have been isolated from the 
brains of humans, nonhuman primates, and rodents (Digicaylioglu et al., 1995, Marti et al., 
1996). Specifically, immunoreactive EPO has been found in the cortex and hippocampus of 
non-diseased human and mouse brain (Bernaudin et al., 1999, Siren et al., 2001a). The ability 
of peripheral or exogenous EPO to cross the BBB has been a topic of debate. In the healthy 
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brain, EPO is thought to cross the BBB at a very slow rate similar to albumin, with brain uptake 
of EPO measured at 0.05% to 0.1% of the injected dose per gram of brain tissue (Banks et al., 
2004). When administered intravenously, the increase in EPO in CSF occurs approximately 3 h 
after administration. EPO transport across the BBB may occur via a first order transmembrane 
or non-receptor mediated mechanism as it follows first-order kinetics (Xenocostas et al., 2005). 
Healthy and schizophrenic patients administered radio-labeled EPO intravenously show defini-
tive evidence of EPO’s ability to cross the BBB, with peak EPO levels occurring at 4 hours after 
administration (Ehrenreich et al., 2004).  
There is also accumulating evidence that exogenous and peripheral EPO cross the BBB 
in even greater amounts in states of CNS injury. In CSF of traumatically brain-injured patients, 
EPO is increased, and the degree of its increase correlates with severity of BBB disruption. In 
studies of normal healthy individuals, EPO has also been detected in the CSF of adults and ne-
onates not administered exogenous EPO, suggesting a role for brain-derived EPO in normal 
brain function and development (Marti et al., 1997). Further evidence of brain-derived EPO 
comes from patient studies demonstrating EPO levels in CSF that do not correlate with serum 
EPO levels. Reports suggest that brain-derived EPO comes from multiple cellular sources. As-
trocytes and neurons from mice have been found to produce EPO (Masuda et al., 1994, Ber-
naudin et al., 1999) while cultured oligodendrocytes from embryonic rat brains, but not mature 
brains, also produce EPO (Sugawa et al., 2002). Together, these studies provide evidence that 
EPO production in the brain has a specific role in development and in normal brain function. In 
addition, peripheral or exogenous EPO can and does cross the BBB in states of health and dis-
ease. The mechanisms by which EPO regulate neural development and its role in the diseased 
brain remain unclear, however, specific cell types involved in EPO production and that express 
EPO-R have been suggested. 
EPO-R is a type I cytokine receptor lacking intrinsic tyrosine kinase ability. EPO-R con-
tains a single transmembrane domain and several cytoplasmic domains, which are associated 
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with JAK2. JAK2 provides tyrosine kinase activity that occurs following EPO binding to an EPO-
R homodimer and conformational change of the EPO-R homodimer. Phosphorylation of EPO-R 
by JAK2 results in signal transduction through STAT5, Akt, MAPK and other pathways. Evi-
dence for the importance of EPO-R in normal development and physiology is abundant. In mice, 
high levels of EPO-R are expressed in the neural tube, peaking at E10.5. By birth, EPO-R ex-
pression is markedly reduced and remains at low levels into adulthood. Human studies show 
similar results with EPO and EPO-R expression occurring between about 7 and 24 weeks of 
fetal development (Juul et al., 1998a, Juul et al., 1998b). Structural changes also occur in the 
brains of EPO and EPO-R knockout mice. Prior to death due to severe anemia, EPO and EPO-
R knockout mice exhibit thinner neuroepithelium, reduced brain size, and hypoplasia of the 
fourth ventricle compared to wild-type littermates (Yu et al., 2002). Neuronal cultures from these 
knockout mice also demonstrate attenuated proliferation and increased sensitivity to hypoxia 
(Liu et al., 1997).  
Together, these studies demonstrate a role of the EPO/EPO-R system in normal brain 
development, some details of which have yet to be elucidated. EPO-R expression has been 
found on multiple cell types within the CNS. Cultured neurons have been found to contain EPO-
R mRNA as well as EPO-R protein (Masuda et al., 1993) as well as astrocytes (Bernaudin et al., 
1999). Interestingly, immunohistochemical analysis has revealed that astrocytic processes sur-
rounding brain capillaries strongly express the receptor. That same study demonstrated EPO-R 
immunoreactivity localized within endothelial cells as well (Brines et al., 2000). 
 
Regulation of EPO and EPO-R in hypoxia/ischemia 
EPO and EPO-R have been shown to be upregulated in hypoxic conditions in vitro and 
in vivo (Tan and Ratcliffe, 1992, Marti et al., 1996). In the brain, EPO mRNA levels have been 
shown to increase up to 20-fold during hypoxic exposure. Although this is less than the reported 
200-fold increase in EPO mRNA increase in the kidney during hypoxia, it is thought to have 
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physiologic relevance (Marti et al., 1996). In a study of human brain autopsy specimens, data 
suggests an upregulation of EPO and EPO-R following ischemic infarct or hypoxic damage in 
the aged human brain as well (Siren et al., 2001b). Cell culture has been used to determine 
which cell types are responsible for the upregulation of EPO in hypoxia. Primary mouse astro-
cytes show a 100-fold increase in EPO expression following hypoxia (Marti et al., 1996, Ber-
naudin et al., 2000). EPO-R mRNA expression also increases in response to hypoxic conditions 
as demonstrated in cultured hippocampal neurons (Chin et al., 2000, Lewczuk et al., 2000). 
Controversy exists regarding the exact mechanism of EPO and EPO-R upregulation in 
states of hypoxia. Most studies support a mechanism involving hypoxia-inducible factor 1 (HIF-
1) transcription of EPO gene (Wenger, 2000), although other evidence exists for a HIF-2 mech-
anism (Rankin et al., 2007). HIF-1 is a highly conserved transcription factor composed of " and 
! subunits. HIF-1! is constitutively expressed in the nucleus, while the "-subunit is hydroxylated 
at proline residues facilitating binding of the von Hippel-Lindau protein, ubiquitination, and sub-
sequent proteasomal degradation in normoxic conditions.  During hypoxia, lack of oxygen inhib-
its the HIF prolyl-hydroxylase due to its use of oxygen as a co-substrate, and ubiquitination and 
degradation of HIF-1" does not occur. When released from degradation, HIF-1" is free to form 
a heterodimer with HIF-1!, which then binds to specific DNA sequences located in hypoxia re-
sponse elements. HIF-1 gene targets include genes involved in angiogenesis, such as VEGF, 
vasomotor control, apoptosis, and erythropoiesis. EPO was the first target gene of HIF-1 to be 
described, and, as evidence suggests, remains an important gene target during conditions of 
reduced oxygen (Wang and Semenza, 1993). 
 
Neuroprotection by EPO in animal models 
 The EPO/EPO-R system has only recently been implicated in the response of the brain 
to ischemia. With the discovery of the human gene for EPO by Lin et al. in 1985, the doors were 
opened for production of EPO for research and clinical purposes. In 1989 the FDA approved the 
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use of EPO (Epogen) for anemia of chronic disease. The first studies describing the neuropro-
tective affect of EPO in animal models of cerebral ischemia utilized permanent occlusion of the 
middle cerebral artery in stroke-prone spontaneously hypertensive rats (Sadamoto et al., 1998). 
The rats were intracerebrally infused with epoietin alpha for 28 days following injury and 
demonstrated an attenuation of post-ischemic navigational disability as well as a reduction in 
infarct volume. Since that initial investigation, the research on EPO as a neuroprotective agent 
has increased greatly. Models of experimental stroke as diverse as devascularization (Kolb et 
al., 2007) and thromboembolic occlusion (Wang et al., 2004), in both permanent (Faure et al., 
2006) and transient (Esneault et al., 2008) ischemia have all reported neuroprotective effects of 
EPO. Neuroprotection has been measured by both reduction in infarct volume (Belayev et al., 
2009) as well as improvement in post-ischemic neurobehavioral assessments (Fletcher et al., 
2009). Likewise, the method of administration and the use of EPO analogs have also been ex-
plored. Intraperitoneal (Li et al., 2009), intracerebroventricular (Kolb et al., 2007), intravenous 
(Villa et al., 2007), and intranasal (Fletcher et al., 2009) administration all provide neuroprotec-
tion. EPO analogs, including non-hematopoietically active ones, have also been shown to re-
duce infarct (Erbayraktar et al., 2003) and improve post-ischemic functional recovery (Villa et 
al., 2007). One study determined the time window for the neuroprotection by EPO by adminis-
tering EPO 24 h before, simultaneously with, 3, 6, and 9 h after ischemic insult and reported 
neuroprotection with EPO administration up to 6 h after experimental stroke (Brines et al., 
2000).  
Despite the abundance of preclinical studies showing neuroprotection by EPO, the 
mechanism by which it acts is not fully understood. One leading hypothesis is that EPO acts to 
inhibit apoptosis in the injured brain, much like its role in erythropoiesis (Villa et al., 2003). Im-
munohistochemical analysis has demonstrated an EPO-mediated attenuation of programmed 
cell death in rats (Siren et al., 2001a) and gerbils (Sakanaka et al., 1998) following experimental 
stroke. Specific mechanisms of apoptosis inhibition that have been elucidated include EPO-
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mediated expression of anti-apoptotic genes bcl-2 and bcl-xL. Likewise, EPO has been shown 
to increase expression of XIAP and c-IAP2, inhibitors of apoptosis genes, in cortical neurons 
(Digicaylioglu and Lipton, 2001). Upon binding of EPO to EPO-R, JAK2 phosphorylation leads 
to phosphorylation and activation of PI3K. EPO-mediated activation of the PI3K/Akt pathway 
serves to inhibit apoptosis by maintaining mitochondrial membrane potential by inhibiting the 
release of cytochrome C and by regulating caspase activity (Chong et al., 2003). Activation of 
Akt also serves to maintain inhibitory phosphorylation of the pro-apoptotic fork head transcrip-
tion factor (FOXO3a), attenuating its ability to activate transcription of apoptotic genes (Mahmud 
et al., 2002). In addition to its role in inhibiting post-ischemic apoptosis, EPO may also play a 
role in reducing the excitotoxic damage that results in the aftermath of the initial cell death. In 
vitro studies in which cell death was triggered by glutamate receptor agonists showed that EPO 
protects neuronal cells from excitotoxicity (Bernaudin et al., 1999, Siren et al., 2001a). Cerebel-
lar granule neurons exposed to hypoxia were also protected by EPO which inhibited calcium-
induced glutamate release (Kawakami et al., 2001). 
Further evidence of the effects of EPO on calcium regulation suggest a potential role of 
this mechanism in EPO-mediated neuroprotection. In vitro studies suggest that EPO may regu-
late calcium flux in neurons by plasma membrane T-type voltage dependent calcium channels 
(Kawakami et al., 2001). In rat striatal slices, EPO has been shown to stimulate dopamine re-
lease and enhance potassium-induced acetylcholine release (Yamamoto et al., 2000), while 
EPO is also associated with increased intracellular concentration of monoamines in a pheo-
chromocytoma cell line (Masuda et al., 1993). Together, these studies suggest that EPO may 
act to stimulate neuronal function, perhaps in the subacute phase of recovery from injury, by 
enhancing calcium channel activation and release of neurotransitters, although more definitive 
studies, including in vivo experiments, are needed.  
 
Clinical trials of EPO for the treatment of ischemic stroke 
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 Due to the success of EPO in preclinical models of stroke, EPO moved into clinical trials 
for the treatment of acute stroke. The first report to be released came from a clinical trial con-
ducted in Germany and was published in 2002. In that initial proof-of-concept trial, researchers 
demonstrated that intravenously administered EPO entered the brain of stroke patients and 
EPO treatment was associated with improvement at 30 days in neurologic scales including the 
NIH Stroke Scale, the Scandanavian Stroke Scale, the modified Rankin scale, and the Barthel 
Index (Ehrenreich et al., 2002). Importantly, patients receiving EPO did not show increases in 
hematocrit, a side effect that would increase risk of re-infarction. A larger clinical trial began in 
2003 and enrolled 522 patients by 2008. Results from this clinical trial were published in 2009 
and did not demonstrate any beneficial effect of EPO as measured by the 90-day Barthel Index. 
In addition, the mortality in EPO treated patients was 16.4% compared to 9.0% in placebo-
treated patients (CI 1.16 to 3.38, p=0.01) (Ehrenreich et al., 2009). The negative result from this 
clinical trial may be attributed to an unknown interaction between tPA and EPO as a high per-
centage (63.4%) of study participants received tPA. Before further clinical trials are conducted, a 
better understanding of EPO’s action in the ischemic brain must be elucidated, including poten-
tial interactions with current standard of care, namely, tPA. 
 
EPO and estrogen 
One possible mechanism by which estrogen worsens stroke outcome is by attenuating 
the hypoxia-induced increases in EPO gene expression. It has long been known that gonadal 
hormones affect erythropoiesis with estrogen having a dampening effect and testosterone in-
creasing hematocrit (Piliero et al., 1968). Reports as early as 1972 suggested that estrogen 
regulates both basal and hypoxia-induced increases in erythropoietin (Peschle et al., 1972). 
More recent studies also demonstrate that estrogen diminishes plasma EPO levels (Wang et al., 
1998) as well as the hypoxia-induced elevation of both EPO and HIF-1" in cell culture (Mukun-
dan et al., 2004). Furthermore, this attenuation is abolished by pre-treatment with the ER inhibi-
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tor ICI 182,780 indicating a receptor-mediated mechanism. Western blot analysis of nuclear 
HIF-1" suggests that estrogen may decrease hypoxia-induced EPO expression by inhibiting 
expression and activity of HIF-1" (Mukundan et al., 2004). In light of recent findings of the dele-
terious effects of estrogen on cerebral ischemia in postmenopausal women, the estrogenic ef-
fects on the EPO/EPO-R system may be a potential mechanism to explain those clinical data, 
and thus warrant further investigation. 
 
Conclusion 
The idea of estrogen as a neuroprotectant first emerged with evidence that pre-
menopausal females experience less damage and greater functional and cognitive recovery 
from neurologic insult than males, with this disparity disappearing around the age of meno-
pause. In hypoxia/ischemia models of neural injury, many studies have shown estrogen to be 
neuroprotective (Simpkins et al., 1997, Toung et al., 1998, Culmsee et al., 1999, Alkayed et al., 
2000) with an equal number of mechanisms postulated to explain these results. Estrogen atten-
uates BBB disruption from neurologic insult, reduces edema, lowers levels of inflammatory me-
diators (Maggi et al., 2004), activates anti-apoptotic pathways (Dziennis et al., 2007), and has 
antioxidant capabilities (Behl et al., 1997) in young animals and cell culture models. Some of 
these actions are receptor-mediated while others have nongenomic mechanisms.  
However, many questions regarding the mechanisms by which estrogen acts remain 
unanswered. Specifically, why is estrogen neuroprotective in young animals, but not in post-
menopausal women? An estimated 10 million women were taking HRT in 2000 for alleviation of 
menopausal symptoms. Then, following the release of reports from the WHI and subsequent 
analyses of that data showing that estrogen increases the incidence and severity of stroke 
(Wassertheil-Smoller et al., 2003, Anderson et al., 2004, Bath and Gray, 2005, Sare et al., 
2008), widespread use of estrogen therapy is no longer recommended. One mechanism worth 
further exploration is the effects of estrogen on the EPO/EPO-R system in the ischemic brain.  
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By more fully understanding the mechanisms of estrogenic action in the aged, injured 
brain, parameters for the safe and effective use of female gonadal hormones may be possible. 
However, most basic science research in neural injury is conducted on healthy, young animals, 
despite the fact that there are age-related differences in estrogenic activity in the brain (Table 
1.1). Animal studies show age-dependent alterations in ER levels following estrogen treatment 
(Belisle et al., 1985, Thakur and Ghosh, 2009), while studies from human cadavers demonstrate 
age-related changes in the specific splice variant of the ER (Ishunina and Swaab, 2008), indi-
cating that aged individuals may have greater levels of a less active form of ER in specific brain 
regions. This disregard of age-dependent differences in the actions of female gonadal hor-
mones, has led to unnecessary patient morbidity and mortality (Anderson et al., 2004); thus, 
research models of disease that account for age-related differences must have a place in future 
investigations of estrogenic activity.
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Figure 1.1. Prevalence of stroke increases with age. Data from the NHANES III demon-
strates that prevalence of stroke increases with age in both men and women (Simon and 
Hudes, 1999). Due to the longer lifespan of women, they experience greater stroke burden over 
their lifetime.  
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Figure 1.2. Estrogenic effects on gp130 signaling. Gp130 signaling plays an important role in 
the injured brain. Although quiescent in the healthy brain, upon injury, STAT3 activation leads to 
transcription of genes that promote cell survival. STAT3 gene deletion studies show enhanced 
neuronal apoptosis as well as increased infarct size after middle cerebral artery occlusion. Es-
trogen has been shown to increase levels of activated STAT3 (Dziennis et al., 2007), however, 
estrogen also increases inhibitors of the pathway, ERK1/2 and SOCS3 (Wong et al., 2003).  
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Figure 1.3. Estrogenic effects on cerebral vasculature. Although ER" immunoreactivity has 
been found in the nucleus, mitochondria and on the membrane of endothelial cells from cerebral 
blood vessels, the role of these receptors in estrogen-mediated vasodilation is unclear. Evi-
dence suggests that estrogenic alteration in myogenic tone occurs via activation of endothelial-
derived nitric oxide synthase and cyclooxygenase-1, which result in vasodilation. 
 
 
37 
Table 1. Reported age-related differences in estrogenic action and receptors in the brain. 
Model Treatment Injury Age-related difference Reference 
post mortem 
human 
- - 
increased MB1 splice variant of ER! in hypothalamus of 
aged women compared to younger women 
(Ishunina and 
Swaab, 2008) 
aged mouse - - 
decreased expression of MTA1 and decreased interaction 
with ER! transactivation domain compared to young adult 
female mice 
(Thakur and Ghosh, 
2009) 
aged female 
mice 
60-day time 
release pellet 
of 1.7mg 
17"-estradiol 
- 
decreased astrocytes and microglial cells in dentate gyrus 
and CA1 compared to young adult female mice 
(Lei et al., 2003) 
aged female rat 
6µg/kg 17"-
estradiol 
(i.v.) 
- 
decreased ER nuclear concentrations in multiple brain re-
gions compared to young adult female rats 
(Wise et al., 1984) 
aged female 
mouse 
0.2µg 17"-
estradiol 
(s.c.) 
- 
decreased ER and decreased binding kinetics of ER in hy-
pothalamus/pituitary compared to young adult female mice 
(Belisle et al., 1985) 
aged female rat 
60-day time 
release pellet 
of 1.0mg 
17"-estradiol 
 forebrain 
excitotoxic 
injury 
increased IL-1" expression, decreased nerve growth factor 
compared to placebo-treated, aged female rats 
(Nordell et al., 2003) 
aged female 
gerbils 
single, high 
dose 4mg/kg 
pre-
treatment 
global is-
chemia 
improved performance on memory tasks, fewer TUNEL and 
caspase 3 positive cells in CA1, CA2 compared to placebo-
treated, aged female gerbils 
(Wappler et al.) 
aged female 
rats 
3-week time 
release pellet 
of 25µg 17"-
estradiol for 
7 days 
filament 
occlusion 
of MCA 
reduced cortical and striatal infarct volume, no changes in 
cerebral blood flow compared to placebo-treated, aged fe-
male rats 
(Alkayed et al., 2000) 
MB1, mamillary body, exon 1; ER, estrogen receptor; MTA1, metastasis associated protein 1; i.v. , intravenous; s.c., subcutane-
ous; IL-1", interleukin-1"; TUNEL, terminal deoxynucleotidyl transferase mediated dUTP nick end labeling; CA, cornu ammonis; 
MCA, middle cerebral artery 
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Chapter Two 
 
Estrogen worsens outcome from middle cerebral artery occlusion in aged rats 
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Abstract 
BACKGROUND AND PURPOSE – Although estrogen is neuroprotective in young adult animal 
models of stroke, clinical trials demonstrate that estrogen increases the incidence and severity 
of stroke in aged women. We have previously shown that experimental stroke pathophysiology 
differs between young adult and aged rats. The aim of this study is to determine the effects of 
estrogen following middle cerebral artery occlusion and reperfusion in young adult and aged 
female rats. 
METHODS – Young adult (3 month) and middle-aged (9 month) female rats were treated with 
subcutaneously implanted pellets containing 17!-estradiol or placebo until they reached 4 
months or 18 months of age, respectively. Focal embolic stroke was performed by middle cere-
bral artery occlusion (2h) with fibrin clot followed by reperfusion with intravenous human recom-
binant tissue plasminogen activator in treated and untreated young adult and aged rats. Histo-
logical and functional outcomes were measured at 24h after middle cerebral artery occlusion. 
RESULTS – Aged rats treated with 17!-estradiol had significantly increased infarct volumes 
compared to placebo-treated aged rats. Young adult rats treated with 17!-estradiol had signifi-
cantly decreased infarct volumes and functional outcome compared to ovariectomized young 
adult rats. Aged female rats treated with 17!-estradiol had decreased post-ischemic GFAP-
positive astrocytes and altered astrocyte morphology. 
CONCLUSIONS – Estrogen acts in an age-dependent manner in the post-ischemic rat brain. In 
young adult rats, estrogen is neuroprotective; chronic estrogen treatment during aging leads to 
worsened ischemic brain injury in aged female rats.  
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Introduction 
The Women’s Health Initiative (WHI) showed for the first time in a large-scale clinical tri-
al that hormone replacement therapy (HRT) was linked to higher incidence of stroke (Was-
sertheil-Smoller et al., 2003). Meta-analyses of the WHI and other smaller clinical trials demon-
strate that women taking estrogen experience greater stroke severity (Bath and Gray, 2005, 
Sare et al., 2008). These findings contradict data from prior animal studies indicating a neuro-
protective role of estrogen (Culmsee et al., 1999, Merchenthaler et al., 2003, Rau et al., 2003, 
Hoffman et al., 2006, Connell et al., 2007, Lebesgue et al., 2009) and raise concerns regarding 
the safe and appropriate use of HRT.  
Aging may be a contributing factor accounting for the contrast between animal stud-
ies and clinical trial findings. Previous studies from our lab underscore the importance of creat-
ing clinically relevant models of disease, which in the case of ischemic stroke includes the use 
of aged animals. Ischemic stroke in aged rats is characterized by increased ische-
mia/reperfusion injury, earlier disruptions of the blood-brain barrier, exacerbated neuronal de-
generation, higher mortality, and reduced functional outcome (Rosen et al., 2005, Dinapoli et al., 
2006, DiNapoli et al., 2008). 
In the present study, we compare the effects of estradiol (E2) administration on ische-
mia/reperfusion injury and functional recovery following experimental stroke between young 
adult and aged female rats. Using a model of transient ischemic stroke with reperfusion, we 
confirmed the findings from previous studies showing that E2 acts as a neuroprotectant in 
young adult female rats. Then, for the first time, we report that chronic E2 administration in aged 
female rats led to worsened ischemic brain injury and increased mortality following experimental 
stroke. The results presented in this study parallel the findings of the WHI in a rat model of is-
chemic stroke and reperfusion and suggest a potential age-related difference in the effects of 
estrogen on stroke.  
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We also investigated a potential pathway to which the age-dependent effects of estrogen 
may be attributed. Previous studies from our lab have shown age-related changes in the Janus 
kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway, a signaling 
cascade known to regulate astrocyte reactivity. Specifically, previous reports demonstrated that 
aged rats have a truncated activation of STAT3 accompanied by enhanced expression of sup-
pressor of cytokine signaling 3 (SOCS3). In the present study, we investigated whether estro-
gen may also exert its age-dependent effects on post-ischemic response through alterations in 
JAK2/STAT3. Despite its importance in the age-related differences in post-ischemic outcome of 
young adult and aged rats, our data do not support a prominent role of the JAK2/STAT3 path-
way by estrogen. Instead, we demonstrate that estrogen treatment in aged female rats acts to 
reduce post-ischemic astrocyte reactivity, has pleiotropic effects on post-ischemic inflammation, 
and decreases expression of estrogen receptor " (ER"). 
 
Materials and Methods 
Chemicals and Animals. Isoflurane was purchased from Halocarbon (River Edge, NJ). Human 
recombinant tissue plasminogen activator (tPA) was gifted from Genentech (South San Francis-
co, CA). E2 and placebo pellets (1.5mg; 90 d release) were purchased from Innovative Re-
search of America (Sarasota, FL). Sixty-five female Sprague-Dawley rats (3 months (N=20) and 
9 months (N=45)) were purchased from Hilltop Animal Laboratory (Scottdale, PA) and housed 
under 12 h:12 h light/dark conditions with food and water provided ad libitum. All procedures 
were in accordance with guidelines set forth by the West Virginia University Animal Care and 
Use Committee.  
Treatment Protocol. Rats were randomly divided, within age groups, into three treatment 
groups. Ovariectomy was performed as follows: at 9 months of age, rats were anesthetized with 
isoflurane (4% induction; 2% maintenance). Once anesthetized, rats were placed on a surgical 
platform and lateral abdominal regions prepped for surgery using aseptic technique. A 10 mm 
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dorsal/ventral incision into the lateral abdomen between the rib cage and hind limb was made 
through the skin. The underlying abdominal muscle was separated with iridectomy scissors to 
expose the ovarian fat pad. Ovaries were excised, muscle layer sutured, and skin incision 
closed using 5-0 absorbable sutures. Topical antibiotic (gentamicin) was applied. Intact rats re-
ceived a sham ovariectomy and were implanted with placebo pellet. OVX rats received bilateral 
ovariectomy and were implanted with placebo pellet. E2 rats were bilaterally ovariectomized and 
implanted with E2 pellet. E2 administration to 3 month old rats lasted for 30 d and pellets in 9 
month-old rats were replaced every 90 d until rats reached 18 months of age (Figure 2.1). Se-
rum E2 was measured at 4 and 18 months using [I125] radioimmunoassay (U of Virginia Ligand 
Core, Charlottesville, VA). All rats underwent a transient ischemic stroke by occlusion of the 
right middle cerebral artery (MCAO) and tPA (5 mg/kg; i.v.) reperfusion under isoflurance anes-
thesia (4% induction, 2% maintenance), as previously described (Dinapoli et al., 2006). Ische-
mia was defined by a perfusion drop across the MCA territory of greater than 80% as deter-
mined by laser Doppler measurement of cerebral blood flow and successful reperfusion was 
denoted as a return to greater than 80% of baseline perfusion rate by 30 min after tPA admin-
istration.  Rats not achieving these standards for depth and duration of ischemia as well as 
reperfusion were excluded from the study.  At 24 h after MCAO, functional assessment was 
measured by an investigator blinded to the treatment using the modified Neurological Severity 
Score (mNSS) (Li et al., 2002). 
Determination of infarct volume and Neuropathology. At 24 h after MCAO, rats were anesthe-
tized with isoflurane, transcardially perfused with 100mL of 0.9% saline, and brains were re-
moved and sliced coronally in 2 mm intervals. Sections were incubated with 2% 2,3,5-
triphenyltetrazolium chloride (TTC) for 15 min at 37°C for determination of infarct volume and 
cerebral edema using methods previously described (Yang et al., 1998). After TTC staining, 
brain slices were fixed in 10% neutral-buffered formalin overnight. Formalin-fixed brain sections 
were embedded in paraffin, cut into 8 µm sections and mounted onto slides. Mounted sections 
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were labeled for degenerating neurons with Fluoro-Jabe B, reactive astrocytes using anti-glial 
fibrillary acidic protein (GFAP; 1:1,000; Dako, Glostrup, DK), microglia using anti-ionic calcium 
binging protein (Iba-1; 1:500; Wako, Richmond, VA), and ER" using anti-ER" (abcam; 1:100; 
Cambridge, MA). Secondary antibody for GFAP, Iba-1, and ER" was biotinylated anti-rabbit IgG 
(1:500, Vector Laboratories, Burlingame, CA). Immunolabeling was visualized by HRP Avidin D 
(1:1000; Vector Laboratories, Burlingame, CA) coupled with 3,3’ diaminobenzidine chromagen 
kit (Vector Laboratories, Burlingame, CA).  Microscopic analysis of GFAP and Iba-1 im-
munostained sections was performed using an Olympus AX70 Provis microscope (Center Val-
ley, PA) and fluorescent confocal microscopy was performed with a Zeiss LSM 510 Confocal 
(v4.2 SP1). 
Real-time PCR amplification. At 12 h after MCAO, rats (n=3 rats/group) were anesthetized with 
pentobarbital sodium (65 mg/kg, i.p.) and transcardially perfused with 100 ml saline (0.9% 
NaCl). Brains were removed and the following regions dissected: ipsilateral (to MCAO) cortex, 
ipsilateral striatum, contralateral cortex, and contralateral striatum and stored in RNAlater. Total 
RNA was isolated and purifed from brain regions using Qiagen RNeasy Mini Kit (Qiagen, Valen-
cia, CA). Concentration and purity of RNA was determined using NanoDrop and considered for 
use only if A260/A280 was between 1.8 and 2.1. Total RNA (1µg) was reverse-transcribed to 
cDNA using SuperScript™ III RNase H- and oligo (dT)12-18 primers (Invitrogen) in a 40µl reac-
tion. Real-time PCR analyses of IL-6, OSM, LIF, TNF", CCL-2, JAK2, STAT3, and BDNF were 
performed using an Applied Biosystems 7500 Real-Time PCR system (Applied Biosystems; 
Foster City, CA) with TaqMan® chemistry. Glyceraldeyde-3-phosphate dehydrogenase 
(GAPDH) was used as an endogenous control to normalize for differences in amount of cDNA 
added to reactions. Specific primers and dual labeled internal fluorogenic (FAM/TAMRA) probe 
sets (TaqMan® Gene Expression Assays) were used according to the manufacturer instructions 
(Applied Biosystems). All PCR amplifications (40 cycles) were performed in a total volume of 
20µl, containing 2µl cDNA, 1µl of the specific Assay on Demand® primer/probe mix, 1µl 
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GAPDH primer/probe mix, and 10µl of TaqMan® Universal master mix (Applied Biosystems). 
Relative quantification of gene expression was performed using the comparative threshold 
(##CT) method as described by manufacturer (User Bulletin 2; Applied Biosystems). Changes in 
mRNA expression level were calculated following normalization to GAPDH and expressed as 
fold change. 
Tissue preparation and immunoblotting. At 24 h following MCAO, rats (n=5 rats/group) were eu-
thanized by focused microwave irradiation (3 kW for 1.5 s) in microwave applicator (Muromachi 
Kikai, Inc; Tokyo, Japan) to preserve steady-state phosphorylation of proteins (O'Callaghan and 
Sriram, 2004, Scharf et al., 2008). Brains were removed and the following regions dissected: 
ipsilateral (to MCAO) cortex, ipsilateral striatum, contralateral cortex, and contralateral striatum 
and stored at -80° C for later use. Following collection of all tissues, brain regions were 
weighed, homogenized in 10 volumes of hot (85–95 °C) 1% SDS, and total protein was deter-
mined by bicinchoninic acid method (Smith et al., 1985) using bovine serum albumin standard. 
Alterations in gp130 signaling pathway were assessed by quantifying total and phosphorylated 
STAT3tyr705 and total and phosphorylated ERK1/2 (42kD and 44kD) using immunoblot analysis 
with detection of fluorescent signals with infrared fluorescence scanner (Licor Biosciences; Lin-
coln, NE). Primary antibodies used included rabbit anti-STAT3 (1:500), rabbit anti-phospho-
STAT3Tyr705 (1:500; Cell Signaling Technology, Inc., Beverly, MA), mouse anti-ERK1/2 (1:500), 
rabbit anti-phospho-ERK1/2Tyr204 (1:500) purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA).  Following incubation with primary antibodies, blots were washed with phosphate 
buffered saline with 0.1% Tween 20 (1 x 15 min; 2 x 5 min) and incubated with fluorescent-
labeled anti-rabbit and anti-mouse IgG antibodies (1:2500) for 1 h. 
Statistical analysis. Data are presented as mean ± S.E. Statistical significance in measured and 
calculated parameters was determined using two-way ANOVA with Tukey’s post-hoc analyses. 
Changes in weight gain were assessed using one-way ANOVA with repeated measures. Mortal-
ity data was assessed with Chi-squared analysis. Level of significance was set at p<0.05. 
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Results 
Confirmation of three distinct treatment groups in 18 month-old rats. Serum E2 levels were 
measured from blood collected before MCAO (Table 2.1). In aged rats, the three treatment 
groups could be differentiated by serum E2 levels. E2 rats had elevated serum E2 levels com-
pared to Intact rats and OVX rats. Serum E2 levels in young adult female rats range from 10 to 
70pg/mL during their 4 day estrous cycle. Serum levels in young adult rats showed that OVX 
rats had a significant reduction in serum E2 as compared to both E2 and Intact rats. No differ-
ence in serum E2 was measured between young adult E2 and young adult Intact rats.  
E2 is neuroprotective in 4 month-old rats following transient ischemia and reperfusion. In young 
adult rats, E2/placebo administration lasted for 30 d at which time rats underwent MCAO with 
tPA reperfusion (n=6/group). Consistent with prior studies, our results demonstrate a significant 
reduction in cortical (p=0.030) and striatal (0.018) infarct volumes at 24 h post-MCAO as com-
pared to young adult OVX rats (Figure 2.2A). No difference in cortical (p=0.728) or striatal 
(p=0.997) infarct volumes were measured between young adult E2 and young adult Intact rats. 
Young adult E2 rats demonstrated a significant improvement in functional outcome, as meas-
ured by mNSS compared to young adult OVX rats (p=0.028) (Figure 2.2B). Of the 20 young 
adult rats in the study, two rats died during MCAO surgery without confirmed infarction and were 
excluded from further analysis. All remaining young adult rats met the ischemia/reperfusion cri-
teria and were included in the study. The mortality rate from ischemic stroke in young adult rats 
was 17% in OVX group and 0% in both Intact and E2 groups. 
E2 exacerbates ischemic brain injury in 18 month-old rats following ischemia and reperfusion 
In aged rats, we measured a significant increase in total infarct volume in E2 rats as compared 
to OVX (p=0.041) and Intact (p=0.028) rats (Figure 2.3A). Most of the increase in E2 infarction 
volume occurred in the cortex. No difference in striatal infarct volume between the treatment 
groups was measured. Assessment of functional outcome by mNSS showed no difference in 
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neurological score between treatment groups at 24h following MCAO (Figure 2.3B). Of the 45 
aged rats in the study, 3 died before reaching 18 months of age, 5 were excluded from analysis 
for not meeting ischemia/reperfusion inclusion criteria. Of the remaining 37 rats, 9 E2, 5 OVX, 
and 6 Intact rats met the inclusion criteria for ischemia/reperfusion, but died before 24h. A signif-
icant increase in mortality rate was observed in E2 rats as compared to Intact rats (Table 2.1). 
No significant differences in cerebral edema were measured between treatment groups (Figure 
2.4). 
E2 increases neurodegeneration and reduces astrogliosis following ischemia and reperfusion. 
E2 rats demonstrated increased neuronal degeneration in both striatum and cortex compared to 
that observed in Intact and OVX rats, but no differences were noted in Fluoro-Jade B staining 
intensity between Intact and OVX rats (Figure 2.5). Reactive astrocytes were labeled using 
GFAP and were most prevalent in ipsilateral striatum and cortex. Compared to Intact and OVX 
rats, E2 rats showed reduced astrocyte hyperplasia in the ipsilateral hemisphere (Figure 2.5). 
High magnification microscopy revealed long, thin astrocytic processes in Intact rats compared 
to fewer and thicker GFAP-positive astrocytic processes in E2 rats (Figure 2.6). Abundance of 
microglia was similar in all rats with microglia in the ipsilateral cortex displaying phagocytic phe-
notype. No morphologic differences in microglia were observed between E2 and Intact groups. 
E2 has pleiotropic effects on post-ischemic inflammation in aged rats. Despite its well-known 
role as an anti-inflammatory agent, estrogen may have different effects on the post-ischemic 
inflammatory response in the aged rat brain. To test the effects of E2 on post-ischemic inflam-
mation, we determined the mRNA levels of three markers of inflammation: interleukin-1! (IL-
1!), tumor necrosis factor-" (TNF-"), and monocyte chemoattractant protein-1 (MCP-1) (Figure 
2.8). Our results indicate that estrogen has pleiotropic effects on post-ischemic inflammation as 
it significantly decreases post-ischemic mRNA levels of IL-1! compared to Intact and OVX rats 
(p<0.001 for both), but has the opposite effect on post-ischemic TNF-" mRNA levels (p<0.001 
compared to both Intact and OVX). Interestingly, the effects of E2 on MCP-1 are not directly re-
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lated to circulating E2 level as Intact and E2 rats both have significantly higher post-ischemic 
MCP-1 mRNA levels compared to OVX rats (p=0.003 and p=0.002, respectively).  
Chronic estrogen supplementation leads to decreased ER! expression. Previous studies have 
suggested that estrogen-mediated neuroprotection in young adult animals is mediated by ER". 
To determine if alterations in ER" expression play a role in the deleterious effects of estrogen in 
the aged female rat brain, we immunolabeled brain sections with ER" antibody (Figure 2.7). In 
all brain sections, ER" immunoreactivity was restricted to the infarcted region and ER"+ cells 
had neuronal morphology. No ER" immunoreactivity was observed in the contralateral (to is-
chemia) hemisphere. In ischemic cortex, E2 rats had reduced numbers of ER"+ cells compared 
to both Intact and OVX rats. In the ischemic striatum, no differences in the number of ER"+ 
cells between treatment groups were observed.  
Estrogenic effects on JAK2/STAT3 signaling. Prior studies have shown that aged animals have 
an altered response of the Janus kinase 2 (JAK2) and signal transducer and activator of tran-
scription 3 (STAT3) pathway following MCAO. To test the effects of estrogen on this pathway 
following MCAO, we measured mRNA levels of cytokine activators of glycoprotein 130 (gp130) 
in the ischemic cortex (Figure 2.9). We found significant increases in interleukin-6 (IL-6) based 
on MCAO in both Intact and OVX treatment groups at 12 hours after MCAO, but not for E2 rats 
(p<0.001 for Intact and OVX, p=0.954 for E2). Compared to Intact rats, E2 rats had a significant 
attenuation in post-ischemic upregulation of both IL-6 (p=0.003) and OSM (p<0.001) mRNA at 
12 hours after MCAO. We also measured JAK2 and STAT3 mRNA levels at 12 hours after 
MCAO and found no significant differences in JAK2 between treatment groups in sham-
operated rats (p=0.267) or following MCAO (p=0.255) (Figure 2.10, panels A, B). Post-ischemic 
STAT3 mRNA was significantly affected by MCAO (p<0.001), but not treatment (p=0.068). No 
significant differences of treatment or MCAO were measured in mRNA levels of BDNF, a gene 
target of STAT3 implicated in post-ischemic recovery (Figure 2.10, panel C). Total STAT3 pro-
tein and phosphorylated (activated) STAT3 protein were measured at 24 hours following MCAO 
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(Figure 2.11). No significant differences were found in total or phosphorylated STAT3 in the is-
chemic cortex.  In the ischemic striatum, phospho-STAT3 was significantly increased in E2 rats. 
Extracellular-signal-regulated kinase1/2 (ERK1/2) is an important modulator of the 
JAK2/STAT3, and, like STAT3 is phosphorylated to be activated. We measured total and acti-
vated protein levels of ERK1/2 and found no significant differences between treatment groups in 
ischemic cortex or ischemic striatum from naïve or treated rats (Figure 2.12).  
 
Discussion 
The present study showed, for the first time, that aged female rats treated with E2 have 
worsened stroke injury and increased mortality following MCAO. Previous reports have shown 
that E2 administered prior to experimental stroke is neuroprotective in young adult rats. Using 
subcutaneously implanted time-release E2 pellets, we confirmed neuroprotection by E2 in 
young adult rats. In contrast, female rats ovariectomized at 9 months of age and administered 
similar E2 pellets until 18 months of age, experienced higher mortality, increased infarct volume, 
and exacerbated neurodegeneration (most pronounced in the cortex) following MCAO. These 
findings support the concept that estrogenic effects on the post-ischemic brain differ over the 
lifespan and demonstrate for the first time, an animal model that produced results that parallel 
findings of the WHI (Wassertheil-Smoller et al., 2003, Anderson et al., 2004).  
The importance of animal models of disease that closely mimic the clinical presentation 
cannot be overstated. This study employed a number of approaches to improve our understand-
ing of estrogenic effects on focal ischemic stroke. First, E2 rats received treatment starting at 9 
months of age and physiologic E2 levels were maintained until 18 months of age, thereby avoid-
ing any prolonged period of hypoestrogenicity. Next, we accounted for the effects of age on 
stroke outcome. Our lab has repeatedly demonstrated that ischemic stroke injury and recovery 
in aged rats (18 to 20 months old) is markedly different from that in younger animal models of 
ischemic injury (Dinapoli et al. 2006). Finally, a method of focal cerebral ischemia implementing 
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embolic occlusion of the middle cerebral artery (MCAO) with tissue plasminogen activator (tPA) 
reperfusion was used to more accurately model the clinical manifestation of thromboembolic 
stroke treated with tPA. Together, these factors support the potential for translating the findings 
from our model into human populations. 
Our results do not support what has become known as the “timing of initiation hypothe-
sis” which claims that a prolonged period of hypoestrogenicity following menopause leads 
to irreversible vascular changes, that are not mimicked in ovariectomized animals immediately 
supplemented with E2 (Wise et al., 2005, Suzuki et al., 2007). A period of hypoestrogenicity is 
thought to contribute to the increased stroke incidence and worsened stroke outcome found in 
women taking HRT. According to proponents of this hypothesis, HRT could be used safely if 
treatment begins close to the time of menopause onset. However, our results show that E2 ad-
ministration initiated at 9 months of age offered no neuroprotection and, in fact, led to higher 
mortality and increased infarct size following MCAO. Likewise, clinical data show that the timing 
of initiation hypothesis is not substantiated in analysis of a subset of WHI participants who be-
gan taking HRT within 5 years of menopause (Prentice et al., 2009).  
The mechanism by which E2 acts following ischemic injury remains unknown. Due to the 
known anti-inflammatory actions of estrogen in young adult animals, we investigated whether 
chronic estrogen supplementation altered the post-ischemic inflammatory response in aged fe-
male rats. We measured mRNA levels of three inflammatory mediators, IL-6, TNF", and MCP-1 
in the ischemic cortex of rats at 12 h after MCAO. We found that E2 supplementation has plei-
otropic effects on inflammation in the post-ischemic brain with post-ischemic E2 rats demon-
strating increases in both TNF" and MCP-1 compared to sham-operated counterparts. Howev-
er, IL-6 levels in E2 rats did not increase following MCAO compared to approximately 20-fold 
increases in Intact and OVX rats following MCAO. TNF", however, was greatly increased in E2 
rats following MCAO and were significantly greater than the post-ischemic increases in both In-
tact and OVX rats. Intact and E2 rats had comparable levels of MCP-1 following MCAO, while 
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OVX rats showed an attenuated post-ischemic increase in MCP-1 mRNA levels. Alongside the 
post-ischemic inflammatory response, cerebral edema commonly complicates the post-ischemic 
recovery. Female gonadal hormones, particularly progesterone, but to some degree estrogen as 
well, are thought to decrease edema resulting from brain injury (O'Donnell et al., 2006). Howev-
er, in aged female rats we did not see any effect of treatment on cerebral edema as measured 
by hemisphere volume comparisons using TTC-stained brains. A more accurate method of cal-
culating cerebral edema, such as dry tissue weight, may find subtle differences between groups. 
Taken together, these findings suggest that estrogen has little effect on the post-ischemic in-
flammatory response as measured by inflammatory cytokine mRNA levels within the ischemic 
tissue and cerebral edema.  
Another potential mechanism of estrogenic action is through alterations or reductions in 
ischemia-induced astrocyte activation. Estrogenic effects on post-ischemic astrocyte response 
have been studied using both traditional immunohistochemistry (Barreto et al., 2007) as well as 
biophotonic/bioluminescent imaging (Cordeau et al., 2008) and demonstrate marked reductions 
in GFAP-positive cells in animals treated with E2 (Barreto et al., 2009). In the present study, we 
assessed presence of astrocyte reactivation using GFAP immunostaining in aged rats and 
found significantly fewer GFAP-positive cells in the ischemic hemisphere of aged E2 rats com-
pared to Intact counterparts. Although the role of reactive astrocytes in the injured brain remains 
unclear, the absence of GFAP protein in knockout mice leads to higher mortality and altered 
astrocyte response to penetrating brain lesion (Pekny et al., 1999). Increased ischemic brain 
injury in E2 rats, and subsequent reduction in GFAP-positive astrocytes, suggest a potentially 
beneficial role of reactive astrocytes in ischemic stroke pathophysiology. Using these findings as 
a foundation, future studies will investigate the effects of E2 on post-ischemic astrocyte re-
sponse.  
Pathways responsible for astrocyte activation following ischemic injury were a likely tar-
get of estrogenic activity and the focus of a subset of experiments in this study. The 
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JAK2/STAT3 signaling cascade has been shown to regulate astrocyte reactivity and has also 
been implicated in age-related differences in post-ischemic response (Dinapoli et al. 2006). We 
assessed both total and phosphorylated STAT3 levels in our aged rat groups at 24 h after 
MCAO and found no differences in protein levels of STAT3 or phospho-STAT3 between groups. 
We also found no differences in protein levels of a key regulator of that pathway, ERK1/2 or the 
activated form, phospho-ERK1/2 between treatment groups. Our Western blot analysis data 
was supported by mRNA results demonstrating both increased and decreased levels of activa-
tors of the g-coupled receptor linked to the JAK2/STAT3 pathway, known as glycoprotein 130 
(gp130). E2 significantly decreased IL-6 mRNA but had the opposite effect on another gp130 
ligand, OSM. Messenger RNA levels of a third gp130 activator, LIF, were not significantly differ-
ent between groups. Taken together, these results do not support the hypothesis that estrogen 
worsens stroke outcome in aged female rats by acting on the JAK2/STAT3 pathway. 
Chronic estrogen supplementation may result in reductions in estrogen receptors that, in 
ischemic conditions, may have in deleterious effects. Specifically, ER" has been implicated in 
the neuroprotective effects of estrogen in young adult rats (Merchenthaler et al., 2003, Dubal et 
al., 2006). ER" knock-out mice administered E2 show a complete reversal of its neuroprotective 
effects, while no differences in E2-mediated neuroprotection are noted in ER! knock-out mice, 
indicating a prominent role of ER" in the neuroprotective action of E2 (Sampei et al., 2000, Du-
bal et al., 2001). To determine whether chronic E2 administration altered the expression levels 
of ER" in aged rats, we immunostained brain sections using ER" antibody. We discovered that 
ER" expression is decreased in E2-treated rats, suggesting that decreases in ER" in the aged, 
chronically E2-treated brain may account for the loss of E2-mediated neuroprotection. This de-
crease in ER" was most pronounces in the cortex of E2 rats, coinciding with the area of in-
creased infarct volume. Interestingly, we also observed that ER" expression was limited to the 
infarct region, indicating that ischemic stimulus is a likely activator of ER" expression. Further-
more, the expression of ER" appeared to be limited to cells with neuronal morphology, contra-
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dictory to previous reports demonstrating ER" in astrocytes of both injured and non-injured 
brains (Spence et al., , Jung-Testas et al., 1992). Together, these results offer further support 
for ER" as mediator of E2-induced neuroprotection, and are a beginning towards determining 
the mechanism of estrogenic action in the aged, post-ischemic brain. 
Despite the clinical relevance of our model, there are several caveats to be considered 
in the present study. Aged OVX rats had significantly higher weight at time of MCAO compared 
to both Intact and E2 rats (Table 2.1). This difference in weight may have resulted in alterations 
in circulating levels of estrone and E2 due to conversion of androstenedione and testosterone in 
adipose tissue (Lukanova et al., 2004). However, levels of E2 measured from blood collected at 
time of sacrifice demonstrated E2 levels below the detectable range in OVX rats. Local conver-
sion of steroid hormones to E2 by the enzyme aromatase may also play a role in stroke patho-
physiology (McCullough et al., 2003), but was not measured in this study. Local aromatase ex-
pression has been shown increase following neural injury, thus future experiments may involve 
post-ischemic quantification of this enzyme (McCullough et al., 2003, Peterson et al., 2004). 
Despite differences in infarct size, aged rats showed no significant differences in functional out-
come following MCAO as measured by the mNSS. This result may be due to limitations of that 
assessment in aged rats. Although useful in young adult rats, the mNSS requires significant mo-
tor coordination to perform many of the subtests in the assessment. Furthermore, due to the 
high mortality in the aged E2 rats, both infarct volumes and mNSS scores may be underesti-
mated by a survivor bias. 
An additional consideration arises from the use of time-release pellets for hormone ad-
ministration. Upon implantation, serum E2 levels increase rapidly followed by a slow decline in 
hormone level, which differs from the more constant hormone levels achieved by oral supple-
mentation in women. Likewise, the E2 used in the laboratory setting differs from commonly pre-
scribed E2. Clinically prescribed conjugated equine estrogen is a mixture of several estrogens, 
with the most common preparation containing estrone sulfate, equilin sulfate, and equilenin sul-
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fate. Further complicating the study of estrogenic effects are reports demonstrating variable lev-
els of the hormone based on patient adiposity (Lukanova et al., 2004), a factor that was not ac-
counted for in the WHI studies. 
 
Summary 
In conclusion, the results of this study are a beginning towards understanding age-
related effects of estrogen in the post-ischemic brain. In the year 2000, an estimated 10 million 
women were taking HRT for the treatment of menopausal symptoms. Since the release of re-
ports from the WHI, FDA guidelines for the use of HRT have been altered to recommend that 
patients take the lowest effective dose for the shortest amount of time. The perceived cardiopro-
tective and neuroprotective actions of estrogen were not substantiated in those clinical trials, 
despite years of animal research to the contrary (Culmsee et al., 1999, Merchenthaler et al., 
2003, Rau et al., 2003, Hoffman et al., 2006, Connell et al., 2007, Lebesgue et al., 2009). Age-
related differences in estrogenic activity may account for those discrepancies. Here, we demon-
strated for the first time deleterious effects of E2 treatment in an aged animal model of ischemic 
stroke, which parallel the findings of the WHI (Wassertheil-Smoller et al., 2003). We also 
demonstrate that estrogenic action in the aged brain is not likely mediated through the 
JAK2/STAT3 pathway. However, we did observe that worsened stroke injury I aged female rats 
was accompanied by downregulation of the ER", suggesting a role for this receptor in estrogen-
mediated neuroprotection. Although further investigation is warranted to gain greater under-
standing of the mechanism(s) of estrogenic actions on the aged brain following ischemic injury, 
development and use of a model that replicates the clinical findings is an essential component 
for progress in the field. 
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Weight (g) Serum E2 
(pg/mL) 
  
Mortality 
(%) 
  Pre 12 mo. 15 mo. 18 mo.   
Intact 342 ± 14 361 ± 7 398 ± 13 400 ± 13 16.4 ± 3.0 40 
OVX 347 ± 12 474 ± 16 500 ± 16 540 ± 14 5.2 ± 0.2 33 
E2 352 ± 11 377 ± 9 396 ± 9 423 ± 27 36.6 ± 3.2 60 
 
Table 2.1. Weight gain, serum E2, and mortality of aged female rats. 
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Figure 2.1. Schematic of serum E2 levels of young adult (A) and aged (B) treatment groups.  
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Figure 2.2. Lack of endogenous or supplemented estrogen leads to increased infarct vol-
ume in young adult rats. (A) Young adult OVX rats demonstrated increased infarct size follow-
ing MCAO with tPA reperfusion compared to both Intact and E2 counterparts. Cortical, striatal, 
and total infarct size were all significantly increased in young adult OVX rats compared to both 
young adult Intact and young adult E2 rats. (B) Lack of endogenous or supplemented estrogen 
led to worsened functional outcome in young adult rats. Young adult OVX rats showed higher 
scores on the modified Neurological Severity Score, indicative of worsened functional outcome. 
There was no significant difference in mNSS scores between Intact and E2 rats. *p<0.05 as 
compared to Intact; #p<0.05 as compared to E2. 
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Figure 2.3. Estrogen treatment leads to increased cortical and total infarct volume in 
aged rats. (A) E2 rats demonstrate increased cortical and total infarct following MCAO with tPA 
reperfusion. There was no significant difference in striatal infarct volume between treatment 
groups. (B) E2 treatment did not significantly alter functional outcome. Aged E2 rats did not 
show worsened functional outcome despite having increased cortical and total infarct volume. 
(C) Representative brain slices from Intact and E2 treated rats demonstrating a significant in-
crease in infarcted tissue in E2 rats. *p<0.05 as compared to Intact; †p<0.05 as compared to 
OVX. 
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Figure 2.4. Estrogen administration does not alter cerebral edema following MCAO. There 
were no significant differences between treatment groups in cerebral edema formation as 
measured at 24 h after MCAO with tPA reperfusion.  
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Figure 2.5.  Exacerbated neurodegeneration and reduced astrogliosis in ischemic hemi-
sphere of aged E2 rats. Fluoro-Jade B staining was used to assess neuronal degeneration at 
24 h after MCAO in ischemic cortex of aged rats. E2 rats (G) had increased neuronal degenera-
tion compared to both Intact (A) and OVX (D) rats. Post-ischemic reactive astrogliosis was ob-
served using anti-glial fibrillary acidic protein (GFAP) and revealed reduced astrogliosis in aged 
E2 rats (H) compared to both Intact (B) and OVX counterparts (E). Inflammatory response was 
assessed with immunostaining of microglia (C, F, I). No significant effect of treatment was ob-
served in microglia immunostaining by Iba-1. Bar = 100$m.  
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Figure 2.6. Reduced GFAP-positive astrocytes and altered astrocyte morphology in aged 
E2 rats. High magnification microscopy of GFAP immunostaining in aged Intact (A) and E2 (B) 
rats revealed fewer GFAP positive cells in ischemic cortex of E2 rats.  Individual astrocytes 
were observed to have fewer and thicker GFAP positive processes in aged E2 rats (D) com-
pared to Intact rats (C). No differences in microglia abundance or morphology were observed in 
aged rats. (E) Intact rats had comparable abundance of Iba-1 positive cells in the ischemic cor-
tex as E2 counterparts (F). Individual cells had similar phagocytic morphology in both Intact (G) 
and E2 (H) rats. Bar (A,B,E,F) = 25$m, (C,D,G,H) = 10$m. 
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Figure 2.7. Estrogen supplementation leads to reduced estrogen receptor-! (ER!) in 
aged female rats. ER" immunolabeled cells in the ischemic cortex and ischemic striatum have 
structural morphology consistent with neurons. ER"-positive cells appear more abundant in the 
ischemic cortex of Intact and OVX rats compared to E2 rats (A, C, E). No observable differ-
62 
ences were noted in abundance of ER"-labeled cells in the ischemic striatum (B, D, F). Scale 
bar = 50µm. 
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Figure 2.8. Estrogen has pleiotropic effects on post-ischemic inflammation. (A) E2 rats do 
not exhibit ischemia-induced increase in interleukin-1! mRNA in the ischemic cortex compared 
to rats lacking endogenous or supplemented estrogen. (B) However, tumor necrosis factor-" 
(TNF") shows the opposite effect with E2 treatment. Intact and OVX rats have TNF" mRNA 
levels increased compared to sham-operated rats, but E2 rats have significantly increased post-
ischemic elevtion of TNF". (C) Monocyte chemoattractant protein (MCP-1) is increased in all 
rats following MCAO compared to sham-operated rats. Intact and E2 rats have significantly 
greater increases in MCP-1 mRNA following ischemia compared to OVX rats. ** p<0.001 com-
pared to E2; ! indicates p <0.01, !! p<0.001 compared to sham-operated; % p<0.01 compared 
to OVX; %% p<0.001 compared to OVX. 
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Figure 2.9. Estrogenic effects on mRNA levels of activators of gp130 signaling in the is-
chemia cortex. E2 rats do not exhibit ischemia-induced upregulation of interleukin-6 (IL-6) 
mRNA following MCAO (A), but do demonstrate post-ischemic increases in leukemia inhibitory 
factor (B) and oncostatin M (C) mRNA compared to sham-operated rats. Post-ischemic upregu-
lation of OSM mRNA is attenuated in E2 rats compared to Intact and OVX groups. *p<0.01, 
**p<0.001 compared to E2; !!p<0.001 compared to sham-operated. 
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Figure 2.10. Estrogen may not act through JAK2/STAT3 following MCAO. Post-ischemic 
alterations in JAK2 (A) and STAT3 (B) mRNA do not show significant differences based on 
treatment group, although there is a significant increase in STAT3 mRNA with MCAO. (C) Brain-
derived neurotrophic factor, a key target of STAT3, does not show alterations dependent on es-
trogen status or MCAO. !!p<0.001 compared to sham-operated rats. 
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Figure 2.11. Estrogen level does not affect activation of STAT3 following MCAO. Total and 
phosphorylated STAT3 proteins were not altered by E2 supplementation at 24 h after MCAO in 
ischemic cortex or ischemic striatum of aged female rats.  
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Figure 2.12. Post-ischemic total and activated ERK1/2 protein are not affected by estro-
gen. Protein levels of neither isoform of ERK1/2 nor their activated forms were altered by estro-
gen status at 24 h after MCAO in ischemic cortex (A) or ischemic striatum (B) of aged female 
rats. 
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Chapter Three 
 
Estrogen down-regulates erythropoietin receptor following middle cerebral artery occlu-
sion in aged female rats 
  
69 
Abstract 
Previous reports have demonstrated that the neuroprotective actions of estrogen in young adult 
animal models of stroke do not translate into aged female rats chronically supplemented with 
estrogen. In the present study we investigate a potential mechanism involved in the deleterious 
effects of estrogen in the aged female rat brain. In rats chronically supplemented with estrogen 
or placebo, we measure a significant reduction in erythropoietin (EPO) receptor mRNA in the 
ischemic cortex following transient occlusion of the middle cerebral artery. We also observe de-
creased EPO-receptor (EPO-R) protein expression in the penumbral cortex and striatum using 
immunohistochemical techniques. In a second group of rats, also treated with estrogen, we at-
tempt to rescue estrogen treated rats from exacerbated stroke injury through administration of 
erythropoietin. Results confirm that EPO administration attenuates estrogen-induced increase in 
infarct volume, and is accompanied by decreased expression of ER" in the ischemic penumbra. 
Together, the results presented here support the hypothesis that chronic estrogen supplementa-
tion leads to reduced brain ER" expression, reduction in post-ischemic EPO-R response, and 
worsened stroke outcome.   
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Introduction 
Previously, combined estrogen and progestin hormone replacement therapy (HRT) was 
widely prescribed to women for the treatment of menopausal symptoms. HRT was thought to 
perpetuate the neuroprotective and cardioprotective actions of endogenous estrogen, since the 
hormone had been repeatedly shown to do so in animal studies (Simpkins et al., 1997, Toung et 
al., 1998, Culmsee et al., 1999, Wang et al., 1999, Alkayed et al., 2000, Dubal and Wise, 2001). 
This clinical practice came into question when the Women’s Health Initiative (WHI) released re-
ports on the effects of HRT (2003) and estrogen supplementation alone (2004) on stroke preva-
lence and outcome (Wassertheil-Smoller et al., 2003, Anderson et al., 2004) that conflicted with 
data from animal studies. In randomized controlled trials of women aged 50–79 years, re-
searchers found an increased risk of ischemic stroke with HRT or estrogen supplementation 
alone, warranting the premature termination of the trials. Since then, meta-analyses of data from 
the WHI and other smaller clinical trials have also shown increased stroke severity with HRT 
(Sare et al., 2008).  
Estrogen is a known modulator of erythropoietin (EPO) and its receptor (EPO-R). Estro-
gen and testosterone have opposite effects on erythropoiesis with estrogen acting to decrease 
erythropoiesis and testosterone acting to increase it (Piliero et al., 1968). Both in vitro and in 
vivo studies indicate that EPO and EPO-R are upregulated in the brain following hypoxic expo-
sure (Chin et al., 2000, Siren et al., 2001b). Yet, estrogen has been shown to decrease hypoxia-
induced upregulation of EPO in cell culture (Mukundan et al., 2004). These effects are likely 
mediated through hypoxia-inducible factor-1 (HIF-1), the HIF-1" subunit of which is released 
from proteasomal degradation in low oxygen conditions (Wang and Semenza, 1993). The spe-
cific mechanism of EPO/EPO-R action in hypoxia is unknown, but experiments in which EPO-R 
is inhibited following ischemia show worsened stroke outcome, suggesting that the EPO/EPO-R 
system is beneficial (Chen et al.). In addition, numerous studies have demonstrated neuropro-
tection by exogenous EPO treatment in acute stroke (Digicaylioglu and Lipton, 2001, Genc et 
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al., 2004, Zhang et al., 2006a, Gonzalez et al., 2007, Ehrenreich et al., 2009). The effects of es-
trogen on the EPO/EPO-R system in the post-ischemic female rat brain have not been explored 
to date, and are the focus of this study. We hypothesized that estrogen may alter the post-
ischemic activation of the EPO/EPO-R system in the aged female rat brain. To test our hypoth-
esis, we administered estradiol (E2) to female rats as they aged and studied the effects of acute 
EPO treatment following transient occlusion of the middle cerebral artery. 
 
Materials and Methods 
Chemicals and Animals. Isoflurane was purchased from Halocarbon (River Edge, NJ). Human 
recombinant tissue plasminogen activator (tPA) was gifted from Genentech (South San Francis-
co, CA). E2 and placebo pellets (1.5mg; 90 d release) were purchased from Innovative Re-
search of America (Sarasota, FL). Sixty-nine female Sprague-Dawley rats (9 months (N=45) 
and 15 months (N=24)) were purchased from Hilltop Animal Laboratory (Scottdale, PA) and 
housed under 12h:12h light/dark conditions with food and water provided ad libitum. All proce-
dures were in accordance with guidelines set forth by the West Virginia University Animal Care 
and Use Committee.  
Treatment Protocol. In the first cohort of animals, nine month-old female rats were randomly di-
vided into three treatment groups: Intact, OVX, and E2. Ovariectomy/sham was performed as 
follows: rats were anesthetized with isoflurane (4% induction; 2% maintenance). Once anesthe-
tized, rats were placed on a surgical platform and lateral abdominal regions prepped for surgery 
using aseptic technique. A 10 mm dorsal/ventral incision into the lateral abdomen between the 
rib cage and hind limb was made through the skin. The underlying abdominal muscle was sepa-
rated with iridectomy scissors to expose the ovarian fat pad. Ovaries were excised, muscle layer 
sutured, and skin incision closed using 5-0 absorbable sutures. Topical antibiotic (gentamicin) 
was applied. Intact rats received a sham ovariectomy and were implanted with placebo pellet. 
OVX rats received bilateral ovariectomy and were implanted with placebo pellet. E2 rats were 
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bilaterally ovariectomized and implanted with E2 pellet. E2 pellets in 9 month-old rats were re-
placed every 90 d until rats reached 18 months of age. In the second cohort of animals, fifteen 
month-old rats were randomly divided into two treatment groups, Intact and E2. At time of 
treatment randomization, they were also randomized to receive EPO or saline following MCAO. 
Intact rats were implanted with placebo pellets, E2 rats received pellets containing 17!-
estradiol, described for the first cohort. Rats in the second cohort also received treatment until 
they reached 18 months of age. Serum E2 was measured at 18 months in all rats using [I125] 
radioimmunoassay (U of Virginia Ligand Core, Charlottesville, VA).  
Middle cerebral artery occlusion. The first cohort of rats underwent a transient ischemic stroke 
by occlusion of the right middle cerebral artery (MCAO) and tPA (5 mg/kg; i.v.) reperfusion un-
der isoflurance anesthesia (4% induction, 2% maintenance), as previously described (Dinapoli 
et al., 2006). Ischemia was defined by a perfusion drop across the MCA territory of greater than 
80% as determined by laser Doppler measurement of cerebral blood flow and successful reper-
fusion was denoted as a return to greater than 80% of baseline perfusion rate by 30min after 
tPA administration.  Rats not achieving these standards for depth and duration of ischemia as 
well as reperfusion were excluded from the study. Intact and E2 rats of the second cohort un-
derwent a transient ischemic stroke by occlusion of the right middle cerebral artery (MCAO) with 
modified suture (Doccol, Redlands, CA) under isoflurance anesthesia (4% induction, 2% 
maintenance). Ischemia was defined by the same criterion as for rats receiving MCAO with fi-
brin clot. Immediately preceding suture removal, a subset of Intact and E2 rats received recom-
binant human erythropoietin (i.p., 5000U/kg). Rats not receiving EPO were administered a simi-
lar injection of vehicle. At 24 h after MCAO, functional assessment was measured by an investi-
gator blinded to the treatment using the modified Neurological Severity Score (mNSS) (Li et al., 
2002). 
Determination of infarct volume and Neuropathology. At 24 h after MCAO, rats were anesthe-
tized with isoflurane, transcardially perfused with 100 mL of 0.9% saline, and brains were re-
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moved and sliced coronally in 2 mm intervals. Sections were incubated with 2% 2,3,5-
triphenyltetrazolium chloride (TTC) for 15 min at 37°C for determination of infarct volume using 
methods previously described (Yang et al., 1998). After TTC staining, one 2 mm brain slice, cor-
responding to the territory of the MCA (0.7 – 2.7 mm from bregma) was fixed in 10% neutral-
buffered formalin overnight. Formalin-fixed brain sections were embedded in paraffin, cut into 8 
µm sections and mounted onto slides.  
Immunohistochemistry. Mounted sections were treated with 0.3% H2O2-30% methanol in PBS to 
suppress endogenous peroxidases. Nonspecific binding was blocked using 10% horse serum. 
Sections were incubated in substrates overnight at 4°C. Brain sections were incubated with bio-
tinylated goat anti-rabbit or horse anti-mouse IgG (Vector Laboratories, Burlingame, CA) fol-
lowed by an avidin-biotin complex process (Vector Laboratories). Finally, the brain sections 
were exposed to stable 3,3'-diaminobenzidine tetrahydrochloride (DAB). EPO-receptor was la-
beled with anti-EPO-R (1:100, Novus Biologicals, Littleton, CO). Microscopic analysis of sec-
tions was performed using an Olympus AX70 Provis microscope (Center Valley, PA) and confo-
cal microscopy was performed with a Zeiss LSM 510 Confocal (v4.2 SP1).  
Real time PCR. Total RNA was isolated from brain homogenates using Qiagen RNeasy Mini Kit 
(Qiagen, Valencia, CA). Only RNA with 260/280 between 1.80 and 2.10 and 260/230. Real time 
PCR analyses of the JAK/STAT array (Table 3.1; SA Biosciences, Frederick, MD) was per-
formed using an ABI PRISM 7700 sequence detection system (Applied Biosystems; Foster City, 
CA) according to manufacturers instructions.  
Enzyme-linked Immunosorbant Assays. Prior to sacrifice, CSF was collected under isoflurane 
anesthesia (4% induction, 4% maintenance) from the cisterna magna. If blood contamination 
occurred during needle withdraw, CSF was centrifuged at 1000 x g for 20 minutes and clear 
CSF was removed and stored at -80° C for later use. Blood was collected from rats transcardial-
ly prior to perfusion. For serum analysis, whole blood was allowed to clot at room temperature 
for 2 hours followed by centrifugation at 1000 x g for 20 minutes. Serum layer was removed and 
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stored at -80° C for later use. EPO, IL-6, and TNF-" levels were determined by ELISA per man-
ufacturer recommendations (R&D Systems, Minneapolis, MN).  
Statistical analysis. Data are presented as mean ± S.E. Statistical significance in measured and 
calculated parameters was determined using two-way ANOVA with Tukey’s post-hoc analyses. 
Level of significance was set at p<0.05.  
 
Results 
Post-ischemic EPO-R downregulation by E2. An array specific to the Janus kinase/signal trans-
ducer and activator of transcription (JAK/STAT) pathway was used to determine the effects of 
chronic E2 supplementation on the post-ischemic alterations in mRNA of effectors in the path-
way in the first cohort of rats, consisting of Intact, E2, and OVX groups. Rats in the first cohort 
received E2 or placebo supplementation from 9 months until 18 months of age. Confirmation of 
differences in serum E2 levels from these rats have been reported on previously (Table 2.1). 
Compared to Intact rats, E2 treatment led to upregulation of prolactin (PRL; 5.0 fold) and prolac-
tin-receptor (PRL-R; 33.1 fold) mRNA in the ischemic cortex. E2 supplementation also caused 
4.9 fold downregulation of EPO-R in the ischemic cortex (Figure 3.1).  
EPO-R expression decreased in ischemic penumbra of E2 rats. Immunohistochemical analysis 
of EPO-R expression in the first cohort of rats indicated a reduced EPO-R expression in rats 
receiving E2 (Figure 3.2). Few EPO-R+ cells were observed within the ischemic core, but differ-
ences in EPO-R expression were noted in the penumbral region, particularly in the penumbral 
cortex. Cells staining for EPO-R had astrocyte and microglia morphology in all treatment 
groups, although a cellular marker was not used to verify cell types. Differences in number of 
EPO-R immunolabeled cells were much less pronounced in the penumbral striatum. 
Confirmation of distinct treatment groups. Serum E2 levels were measured from blood collected 
prior to pellet implantation and after 75 days in the second cohort of rats which were treated with 
E2 or placebo from 15 months until 18 months of age (Figure 3.3). At baseline, prior to treat-
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ment group randomization, no differences were measured in serum E2 levels. Following 75 
days of E2 treatment, however, two distinct treatment groups could be differentiated by serum 
E2 level, where rats treated with E2 had significantly elevated serum E2 levels compared to In-
tact rats.  
Enzyme-linked immunosorbent assay for EPO in cerebrospinal fluid and serum. Results from 
ELISA for EPO in CSF and serum of Intact and E2 rats revealed significantly higher levels of 
EPO in the CSF of Intact rats compared to their respective serum EPO level (Figure 3.4). How-
ever, despite EPO administration in a subset of each treatment group, no significant differences 
were measured in serum or CSF levels of EPO between EPO and saline treated rats, potentially 
indicating unreliable results.  
Effects of chronic E2 and acute EPO in post-ischemic markers of systemic inflammatory. Post-
ischemic serum tumor necrosis factor " (TNF") and interleukin-6 (IL-6) were measured by en-
zyme-linked immunosorbent assay to determine systemic inflammatory profile (Figure 3.5). Se-
rum TNF" was significantly increased by E2 treatment (p=0.003), but not by EPO administration 
(p=0.081). TNF" levels were increased by EPO treatment in E2 rats from 8.5 ±1.9 pg/mL to 
16.5 ± 2.1 pg/mL, but this increase was not statistically significant. IL-6 levels in Intact and E2 
rats treated with EPO were increased compared to saline treated rats (346 ± 87 pg/mL com-
pared to 218 ± 98 pg/mL in Intact rats, and 392 ± 87 pg/mL compared to 177 ± 65 pg/mL in E2 
rats), but this difference also did not reach significance (p=0.076). 
Acute treatment with EPO reduces infarct volume in estrogen-treated rats. At 2 h following initia-
tion of cerebral ischemia by suture occlusion of the middle cerebral artery, a subset of Intact and 
E2 rats (n=4/group) received 5,000 U/kg of EPO (i.p.). Infarct volume was measured at 24 h af-
ter initiation of MCAO (Figure 3.6, panel A). Cortical infarct volume of E2 rats was higher than 
that of EPO and saline treated Intact rats as well as E2 + EPO rats, but it did not reach signifi-
cance (p=0.182). There were no differences based on E2 or EPO treatment in striatal infarct 
volume. Total infarct volume showed a significant effect of EPO treatment (p=0.044), although 
76 
no differences in functional impairment following MCAO were measured between groups using 
the modified Neurological Severity Score (Figure 3.6, panel B).  
E2 supplementation is associated with greater post-ischemic disruption of tissue architecture 
and presence of petechial hemorrhage, which is reduced by acute EPO treatment. Brain sec-
tions from the middle cerebral artery territory from rats in each treatment group were stained 
with hematoxylin and eosin at 24 h after MCAO and studied for cellular and structural alterations 
(Figure 3.7). E2 supplementation was associated with enhanced disruption of tissue architecture 
and accompanied by petechial hemorrhage, most pronounced in the ischemic cortex. This dis-
ruption of tissue architecture was attenuated in E2 rats receiving acute EPO treatment. In Intact 
rats, EPO treatment enhanced tissue vacuolation in the cortex, but did not affect the ischemic 
striatum. 
Both EPO-R and ER! expression are attenuated in the post-ischemic, estrogen treated rat 
brain. At 24 h after MCAO, brain sections from Intact and E2 rats receiving saline or EPO were 
immunolabeled with EPO-R or ER". Similar to results from the first cohort of rats, ER"+ cells 
were only present in the ischemic core with some extent into the penumbra. No ER"+ cells were 
observed in the contralateral hemisphere or outside the territory of the MCA. Cellular morpholo-
gy of ER"+ cells was consistent with that of neurons, although no cellular marker was used. No 
pronounced differences in ER" expression were observed based on EPO treatment. A promi-
nent decrease was observed in the number of ER"+ cells in the penumbral regions of E2 rats 
treated with saline compared to both EPO and saline treated Intact rats. In contrast, EPO-R im-
munolabeling was present only in the penumbral region and was not observed in the ischemic 
core in any treatment group (Figure 3.9). EPO-R+ cells extended into the contralateral hemi-
sphere and were abundant in the corpus callosum of all rat brains studied. EPO-R+ cells had 
morphology consistent with that of astrocytes or microglia. No EPO-R+ cells with neuronal mor-
phology were observed. No differences in number of EPO-R+ cells were noted based on EPO 
treatment, however E2 rats were observed to have reduced EPO-R+ cells both in the penum-
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bral cortex as well as the penumbral striatum, similar to results observed in the first cohort of 
rats. 
 
Discussion 
E2 has been repeatedly shown to be neuroprotective in young adult animal models of 
stroke. However, we have previously reported that female rats treated with E2 during aging ex-
perience exacerbated infarct volume compared to age-matched, placebo treated rats. In the 
present study, we examined a potential mechanism by which estrogen worsens cerebral injury 
following experimental stroke in aged female rats. Our data suggest that deleterious effects of 
estrogen in the aged female rat brain may be linked to the post-ischemic EPO/EPO-R system. 
In the first cohort of female rats, treated with E2 from 9 months until 18 months, we demonstrate 
an almost 5-fold downregulation of EPO-R mRNA in the ischemic cortex. Analysis of EPO-R 
protein expression by immunohistochemistry revealed significantly fewer EPO-R+ cells in rats 
receiving E2, as well. In contrast, previous studies reported in the literature both in vitro and in 
vivo demonstrate upregulation of EPO-R in neurons and glia cells following hypoxic/ischemic 
insult (Chen et al.). Administration of EPO has been demonstrated to have neuroprotective ca-
pacity in preclinical models of stroke. These reports, together with our findings, support the no-
tion that effects of estrogen to worsen stroke injury involve downregulation of EPO-R. 
Based upon our initial findings, we designed a second experiment in which E2 and pla-
cebo treated rats received EPO treatment (5,000 U/kg, i.p.) at 2 h after the initiation of ischemia. 
If EPO-R reduction were responsible for increased infarct size in E2-treated rats, we hypothe-
sized that treatment with EPO would rescue E2 rats from worsened stroke injury. Furthermore, 
based upon previous preclinical reports, we expected EPO to have neuroprotective qualities, 
leading to reduced infarct volume in placebo treated aged female rats. EPO has been studied 
extensively in young adult animal models and, based upon those preclinical studies, moved to 
clinical stroke trials (Ehrenreich et al., 2002). In Phase II trials, EPO failed to improve stroke 
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outcome and was associated with an increased mortality, leading to the termination of its devel-
opment as a stroke therapeutic (Ehrenreich et al., 2009). The failure of EPO in clinical trials may 
be attributable to the lack of thorough investigation into its mechanism of action in a clinically 
relevant animal model. In addition, the majority of patients receiving EPO that subsequently died 
were reported to have also received tPA. Clinical researchers speculate as to whether an un-
recognized tPA-EPO interaction could have occurred, leading to the detrimental outcome. For 
this reason, we chose to use the suture occlusion model of MCAO in the second cohort of E2 
and placebo treated rats in order to permit reperfusion without the use of tPA.  
 At 24 h after MCAO by suture occlusion, we calculated a significant reduction in total in-
farct volume in rats receiving EPO, supporting our hypothesis that EPO administration to E2 rats 
could return their infarct size to baseline levels for aged rats. No statistically significant differ-
ences were measured in cortical or striatal infarct volumes, however, this may be due to the 
small sample size used in our second study (n=4/group). Particularly in the cortex, there was a 
trend toward decreased cortical infarct volume with EPO treatment in E2 rats (p=0.182). We did 
not, however, find an improvement in infarct volume with EPO treatment in Intact rats, as has 
been reported in the past using young adult animals. Histologic evaluation of ischemic sections 
revealed greater disruption of tissue architecture with E2 treatment, which was attenuated in E2 
rats receiving EPO. Functional assessment with the mNSS, however, did not support the notion 
of worsened stroke injury in E2 rats or attenuation by EPO treatment. Previous reports from our 
lab have demonstrated that aged rats provide unique challenges to post-ischemic functional 
testing due to reduced basal locomotor activity. Therefore, data showing null differences in func-
tional outcome between groups as measured by the mNSS does not provide a complete profile 
of post-ischemic functional impairment.   
Although this data does not prove causality, namely that E2-mediated downregulation of 
EPO-R leads to exacerbated stroke injury which is corrected by acute EPO treatment, this study 
provides supporting evidence for that hypothesis and an avenue for further exploration into the 
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mechanisms of estrogenic action in the ischemic brain. To better understand how estrogen reg-
ulated EPO-R expression in the post-ischemic brain, we performed immunohistochemistry for 
ER", the estrogen receptor implicated in estrogen-mediated neuroprotection in young adult an-
imals (Sampei et al., 2000, Dubal et al., 2001, Dubal et al., 2006). We observed that aged rats 
treated with E2 have reduced ER" expression, which is most pronounced in the penumbral cor-
tex and striatum. ER" expression was not affected by EPO treatment, as expected. Taken to-
gether, our findings support a proposed mechanism of estrogenic action in the post-ischemic 
brain where chronic estrogen supplementation leads to reduced ER" expression which, in turn, 
reduces EPO-R expression and exacerbates ischemic injury. In this proposed mechanism, and 
supported by our data, it is the EPO/EPO-R system, rather than estrogen directly that confers 
neuroprotection and is altered by chronic E2 treatment. However, there are many additional de-
tails left unexplained in this proposed model, thus warranting further study. Most importantly, 
perhaps, is the question of age-related differences in estrogenic action.  
 In addition, the present study has some limitations and leaves some questions unan-
swered. First and foremost are the unexpected results from the EPO ELISA which do not show 
elevated serum EPO in rats receiving EPO and show significantly higher levels of EPO in the 
CSF compared to the serum in all treatment groups. The most plausible conclusion to draw from 
this experiment is that the ELISA did not accurately measure EPO levels. There are two main 
reasons why this may be true: 1) EPO levels from samples were calculated from the equation of 
the best fit line of the standard curve and were outside the range of the standards, thus limiting 
the accuracy of the assay, and 2) samples containing lysed red blood cells can alter results from 
colorimetric ELISAs, and some samples did have hemolysis present. The second caveat in-
volves the type of estrogen supplementation used, which is unlike commonly prescribed estro-
gen therapy. Clinically prescribed conjugated equine estrogen is a mixture of several estrogens, 
with the most common preparation containing estrone sulfate, equilin sulfate, and equilenin sul-
fate In contrast, laboratory studies, like the one presented here, use the most active form of es-
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trogen, 17!-estradiol in a time-release matrix or silastic capsule. This time-release matrix is also 
imperfect, and upon implantation, serum E2 levels increase rapidly followed by a slow decline in 
hormone level; this dosage profile differs from the more constant hormone levels achieved by 
oral supplementation in women.  
Finally, a potentially clinically relevant result from our studies that is likely unrelated to 
exacerbation of stroke injury, warrants discussion. In the debate surrounding HRT, stroke sever-
ity is not the major concern; rather, the increased risk of stroke in women taking HRT or estro-
gen alone is the primary focus of discussion. Based on the data from our JAK/STAT array, we 
propose that estrogenic effects on the PRL/PRL-R system may account for increased stroke risk 
in women taking HRT or estrogen alone. In our first cohort of rats, E2 supplementation led to 
alterations in PRL and PRL-R in the post-ischemic brain, specifically, a 5-fold upregulation of 
PRL mRNA and a 33-fold upregulation of PRL-R mRNA at 12 hours after MCAO. Research has 
indicated that PRL-R is present on hematopoietic tissue and PRL/PRL-R activity is implicated in 
the promotion of clot formation, specifically affecting platelets (Dardenne et al., 1994).  
Observational support of the role of PRL and PRL-R comes from pregnant and puerperi-
um women, states in which stroke and venous thromboembolism (VTE) risk is the highest in 
women under age 50 and which coincides with the time of increased PRL (Wallaschofski et al., 
2001). Likewise, females taking hormonal birth control or hormone replacement therapy are also 
at increased risk of VTE and stroke (Pymar and Creinin, 2001), and, as demonstrated in an an-
imal model here, have elevated PRL and PRL-R mRNA in the brain. The mechanism by which 
PRL enhances clotting is thought to involve upregulation of P-selectin, an adhesion molecule on 
the surface of platelets that enhances platelet aggregation (Raaz et al., 2006). It is unknown if 
PRL acts within the brain to enhance clotting or if PRL/PRL-R are involved in stroke risk or out-
come. However, considering the supposed platelet-activating actions of PRL and the effects of 
E2 to increase PRL and PRL-R in the brain, further investigation is warranted.  
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Summary 
 Preclinical studies have demonstrated that estrogen is neuroprotective in young adult 
animal models of stroke. We have previously demonstrated that estrogen does not confer neu-
roprotection in the aged female rat model of stroke, and, in fact, increases mortality and exacer-
bates ischemic brain injury. In the present study, we show that in the same estrogen-treated rats 
that exhibited increased mortality and worsened stroke injury, there was downregulation of 
EPO-R mRNA in the ischemic cortex accompanied by reduced EPO-R protein expression, as 
observed by immunostaining. In a second cohort of aged female rats treated for 90 days with 
estrogen or placebo, we demonstrate attenuation of the estrogenic effects on infarct size with 
administration of EPO at 2 h after initiation of MCAO. EPO treatment also reduced disruption of 
tissue architecture and pettichae formation within the ischemic parenchyma. Lastly, we observe 
reduced ER" protein expression in the same aged female rats. Together, these data support 
the hypothesis that chronic estrogen supplementation reduces ER" expression and subse-
quently inhibits post-ischemic EPO-R expression resulting in worsened stroke injury. There re-
main significant questions to be answered in order to validate and gain a better understanding 
of this proposed model of estrogenic action in the post-ischemic aged rat brain. 
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Unigene GeneBank Symbol Description Gene Name 
 
Unigene GeneBank Symbol Description Gene Name 
Rn.198688 NM_012488 A2m Alpha-2-macroglobulin 
A2MAC1, A2m1, 
A2maa, 
MGC114358, Mam, 
RATA2MAC1 
 
Rn.90070 NM_012576 Nr3c1 Nuclear receptor subfamily 3, group C, member 1 GR, Gcr, Grl 
Rn.163202 NM_053669 Sh2b2 SH2B adaptor protein 2 Aps 
 
Rn.127158 NM_001006961 Osm Oncostatin M - 
Rn.10323 NM_031535 Bcl2l1 Bcl2-like 1 
Bcl-xl, Bcl2l, Bclx, 
bcl-X  
Rn.55127 XM_214030 Pdgfra 
Platelet derived growth factor receptor, alpha 
polypeptide 
APDGFR, PDGFACE 
Rn.22279 NM_171992 Ccnd1 Cyclin D1 - 
 
Rn.24369 XM_217188 Pias1 Protein inhibitor of activated STAT, 1 - 
Rn.10089 NM_080782 Cdkn1a 
Cyclin-dependent kinase 
inhibitor 1A (p21, Cip1) 
Cip1, Waf1 
 
Rn.9759 NM_012629 Prl Prolactin 
PRLB, PRLSD1, Prl1a1, Prol, 
RATPRLSD1, RNPROL 
Rn.6479 NM_024125 Cebpb 
CCAAT/enhancer binding 
protein (C/EBP), beta 
Il6dbp, LAP, NF-
IL6, TCF5  
Rn.9757 NM_012630 Prlr Prolactin receptor MGC105486, RATPRLR 
Rn.163154 NM_019302 Crk 
V-crk sarcoma virus CT10 
oncogene homolog (avian) 
Crko 
 
Rn.11317 NM_012637 Ptpn1 Protein tyrosine phosphatase, non-receptor type 1 MGC93562, Ptp 
Rn.16463 NM_017096 Crp 
C-reactive protein, pentraxin-
related 
Aa1249, Ab1-341, 
Ab2-196, Ac1-114, 
Ac1262, Ac2-069, 
Ba2-693 
 
Rn.53971 NM_013016 Sirpa Signal-regulatory protein alpha Bit, Ptpns1, SHPS-1 
Rn.72599 NM_001029901 Csf1r 
Colony stimulating factor 1 
receptor 
CSF-1-R, 
MGC125014, c-fms  
Rn.90166 XM_001062978 Ptprc Protein tyrosine phosphatase, receptor type, C CD45, L-CA, Lca, RT7, T200 
Rn.42930 NM_133555 Csf2rb 
Colony stimulating factor 2 
receptor, beta, low-affinity 
(granulocyte-macrophage) 
Csf2rb1 
 
Rn.11295 NM_145779 Pzp Pregnancy-zone protein - 
Rn.7391 NM_145672 Cxcl9 
Chemokine (C-X-C motif) 
ligand 9 
MGC105312, Mig, 
Scyb9  
Rn.22261 XM_221655 Il10rb Interleukin 10 receptor, beta RGD1560373 
Rn.37227 NM_031507 Egfr 
Epidermal growth factor 
receptor 
ERBB1, ErbB-1, 
Errp  
Rn.145609 XM_001067317 
RGD15620
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Similar to Src-like adaptor protein-2 - 
Rn.22394 NM_017002 Epor Erythropoietin receptor MGC108723 
 
Rn.162251 XM_001067909 Stam 
Signal transducing adaptor molecule (SH3 domain 
and ITAM motif) 1 
RGD1564499 
Rn.54498 NM_022924 F2 
Coagulation factor II 
(thrombin) 
- 
 
Rn.47568 XM_575987 Socs5 Suppressor of cytokine signaling 5 RGD1564914 
Rn.2609 NM_012950 F2r 
Coagulation factor II 
(thrombin) receptor 
MGC93622, Par1, 
TRGPC  
Rn.212982 NM_001005892 Sfpi1 SFFV proviral integration 1 Pu.1 
Rn.9677 NM_012724 Fcer1a 
Fc fragment of IgE, high 
affinity I, receptor for; alpha 
polypeptide 
Iger01, 
RATIGER01  
Rn.11069 NM_134456 Sh2bpsm1 SH2-B PH domain containing signaling mediator 1 Sh2-b, Sh2b 
Rn.16643 XM_215643 Fcgr1a 
Fc fragment of IgG, high 
affinity Ia, receptor (CD64) 
FcgammaRI, Fcgr1, 
Fcgr1b  
Rn.10635 NM_013130 Smad1 SMAD family member 1 Madh1 
Rn.198318 XM_216605 G1p2 
Interferon, alpha-inducible 
protein (clone IFI-15K) 
- 
 
Rn.2755 NM_019191 Smad2 SMAD family member 2 MGC156656, Madh2 
Rn.92350 NM_133293 Gata3 GATA binding protein 3 - 
 
Rn.10636 NM_013095 Smad3 SMAD family member 3 Madh3 
N/A XM_221882 Gbp1 
Guanylate binding protein 1, 
interferon-inducible, 67kDa 
- 
 
Rn.9774 NM_019275 Smad4 SMAD family member 4 Madh4 
Rn.2178 NM_017094 Ghr Growth hormone receptor 
GHR, BP, 
MGC124963, 
MGC156665 
 
Rn.146857 NM_021692 Smad5 SMAD family member 5 Madh5 
Rn.83614 NM_139327 Hmga1 
High mobility group AT-hook 
1 
Hmgi, Hmgiy 
 
Rn.82754 NM_145879 Socs1 Suppressor of cytokine signaling 1 Cish1, Socs-1 
Rn.105738 XM_213649 Ifnar1 
Interferon (alpha, beta and 
omega) receptor 1 
- 
 
Rn.205056 NM_058208 Socs2 Suppressor of cytokine signaling 2 Cish2, Socs-2 
Rn.10795 NM_138880 Ifng Interferon gamma IFNG2 
 
Rn.127801 NM_053565 Socs3 Suppressor of cytokine signaling 3 Cish3, Socs-3, Ssi-3 
Rn.19927 NM_053783 Ifngr1 Interferon gamma receptor 1 Ifngr 
 
Rn.62929 XM_223934 Socs4 Suppressor of cytokine signaling 4 - 
Rn.64632 NM_057193 Il10ra Interleukin 10 receptor, alpha - 
 
Rn.44609 NM_012655 Sp1 Sp1 transcription factor - 
Rn.9872 NM_013163 Il2ra Interleukin 2 receptor, alpha IL2RAC 
 
Rn.112600 NM_031977 Src 
V-src sarcoma (Schmidt-Ruppin A-2) viral oncogene 
homolog (avian) 
- 
Rn.14508 NM_080889 Il2rg 
Interleukin 2 receptor, 
gamma 
Ab2-183, Cd132 
 
Rn.33229 NM_032612 Stat1 Signal transducer and activator of transcription 1 - 
Rn.108255 NM_201270 Il4 Interleukin 4 Il4e12 
 
Rn.24237 NM_001011905 Stat2 Signal transducer and activator of transcription 2 - 
Rn.10471 NM_133380 Il4ra Interleukin 4 receptor, alpha Il4r 
 
Rn.10247 NM_012747 Stat3 Signal transducer and activator of transcription 3 MGC93551 
Rn.12138 NM_001008725 Il6st 
Interleukin 6 signal 
transducer 
Ac1055 
 
Rn.137580 NM_001012226 Stat4 Signal transducer and activator of transcription 4 - 
Rn.6396 NM_012591 Irf1 Interferon regulatory factor 1 - 
 
Rn.154399 NM_017064 Stat5a Signal transducer and activator of transcription 5A Stat5 
Rn.163277 NM_001012041 Irf9 Interferon regulatory factor 9 Isgf3g 
 
Rn.54486 NM_022380 Stat5b Signal transducer and activator of transcription 5B - 
Rn.90191 XM_342872 Jak1 Janus kinase 1 - 
 
Rn.6880 XM_343223 Stat6 Signal transducer and activator of transcription 6 - 
Rn.18909 NM_031514 Jak2 Janus kinase 2 - 
 
Rn.6504 NM_001025625 Stub1 STIP1 homology and U-Box containing protein 1 MGC116422 
Rn.11159 NM_012855 Jak3 Janus kinase 3 RATJAK3 
 
Rn.162521 NM_139194 Fas Fas (TNF receptor superfamily, member 6) Tnfrsf6 
Rn.93714 NM_021835 Jun Jun oncogene - 
 
Rn.140313 XM_233741 Tyk2 Tyrosine kinase 2 - 
Rn.15806 NM_021836 Junb Jun B proto-oncogene - 
 
Rn.10845 NM_031777 Usf1 Upstream transcription factor 1 - 
Rn.47894 NM_001024344 Sit1 
Signaling threshold 
regulating transmembrane 
adaptor 1 
- 
 
Rn.162877 NM_173290 Yy1 YY1 transcription factor NF-E1, UCRBP 
Rn.222008 XM_001060362 Il20 Interleukin 20 - 
 
Rn.973 NM_001007604 Rplp1 Ribosomal protein, large, P1 MGC72935 
Rn.32086 NM_133523 Mmp3 Matrix metallopeptidase 3 - 
 
Rn.47 NM_012583 Hprt1 Hypoxanthine phosphoribosyltransferase 1 Hgprtase, Hprt, MGC112554 
Rn.198731 XM_345572 Mpl 
Myeloproliferative leukemia 
virus oncogene 
- 
 
Rn.92211 NM_173340 Rpl13a Ribosomal protein L13A - 
Rn.12072 NM_012603 Myc Myelocytomatosis oncogene 
MGC105490, 
RNCMYC, c-myc, 
mMyc 
 
Rn.107896 NM_017025 Ldha Lactate dehydrogenase A Ldh1 
Rn.2411 XM_342346 Nfkb1 
Nuclear factor of kappa light 
polypeptide gene enhancer 
in B-cells 1 
NF-kB 
 
Rn.94978 NM_031144 Actb Actin, beta Actx 
Rn.10400 NM_012611 Nos2 
Nitric oxide synthase 2, 
inducible 
Nos2a, iNos 
      
Table 3.1. Probes tested in JAK/STAT array  
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Figure 3.1. Estrogen supplementation leads to downregulation of EPO-R mRNA following 
MCAO. Post-ischemic mRNA levels of modulators of the JAK/STAT signaling pathway were 
measured at 12 h following MCAO in the first cohort of rats. Compared to Intact rats, E2 rats 
had increased mRNA levels of prolactin (PRL) and prolactin-receptor (PRL-R) and nearly a 5-
fold decrease in EPO-R mRNA. Level of significance set at p<0.05, indicated by lines surround-
ing center line.  
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Figure 3.2. Estrogen treated rats have reduced EPO-R immunostaining in the ischemic 
penumbra. Immunostaining for EPO-R in the first cohort of rats was most prominent in all sam-
ples in the penumbral region and was not observed in the ischemic core. Compared to both In-
tact (A, B) and OVX (C, D) rats, E2 rats had reduced post-ischemic EPO-R immunolabeling (E, 
F), most pronounced in the penumbral cortex (E). EPO-R immunostaining was observed to be 
most prominent in the penumbral cortex of OVX rats (C). Scale bars = 100µm. 
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Figure 3.3. Significant difference in serum E2 levels between E2 and placebo treated rats. 
Serum E2 levels from the second cohort of rats prior to randomization at 15 months of age (Pre) 
and two weeks before MCAO, at 18 months of age (Post). Rats treated with pellets containing 
17!-estradiol had significantly higher serum E2 levels at 18 months compared to rats adminis-
tered placebo pellets. *p<0.05 compared to placebo treated rats using one-way ANOVA with 
Tukey’s post hoc analysis. 
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Figure 3.4. Serum and CSF levels of EPO. Serum and CSF were collected at time of sacrifice 
at 24 h after MCAO in the second cohort of rats and EPO levels were measured by enzyme-
linked immunosorbent assay. (A) There were no significant differences in serum EPO levels be-
tween treatment groups. (B) Statistical analysis could not be performed on CSF levels from E2 
groups due to a sample size of one in E2 + EPO group. 
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Figure 3.5. Serum tumor necrosis factor-! is increased by estrogen. (A) TNF-" levels were 
measured in serum by enzyme-linked immunosorbant assay in the second cohort of rats. A 
subset of Intact and E2 rats received EPO (i.p., 5000U/kg). In Intact rats, EPO had little effect 
on TNF-" levels, while E2 treatment led to a significant increase in TNF-" that was further in-
creased by EPO treatment. (B) E2 supplementation did not have significant effects on serum 
interleukin-6 levels. EPO treatment tended to increase serum IL-6 levels in rats at 24 h after 
MCAO, but data did not reach significance (p=0.07). *p<0.05 compared to Intact rats using two-
way ANOVA with Tukey’s post hoc analysis. 
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Figure 3.6. Acute treatment with EPO reduces infarct volume in estrogen treated rats. 
Modified Neurologic Severity Score and infarct volume were measured at 24 h after MCAO in 
the second cohort of Intact and E2 rats. (A) EPO treatment at 2 h after initiation of MCAO did 
not significantly alter cortical, striatal, or total infarct volume in Intact rats. In E2 rats, EPO treat-
ment resulted in significantly decreased total infarct volume (p=0.04). EPO also decreased cor-
tical infarct volume in E2 rats, but not significantly (p=0.07). (B) No significant differences be-
tween groups were measured in composite mNSS score. *p<0.05 compared to EPO treated 
rats using two-way ANOVA with Tukey’s post hoc analysis. 
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Figure 3.7. Estrogen leads to greater disruption of tissue architecture and petechial hem-
orrhage following MCAO. Coronal tissue sections from the infarcted region of rats from the 
second cohort were stained with hematoxylin and eosin. Overall, saline treated Intact rats (A, B) 
showed less necrotic damage in the ischemic hemisphere than E2 rats (E, F). Post-ischemic 
disruption of tissue architecture was observed in the ischemic hemisphere in all specimens, but 
90 
was most pronounced in the ischemic cortex of E2 rats not receiving EPO (E, F). Acute treat-
ment with EPO reduced post-ischemic disruption of tissue architecture in E2 rats (G, H) but led 
to increased tissue vacuolation in both Intact (C, D) and E2 rats (G, H). Scale bars = 100µm. 
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Figure 3.8. E2 rats show reduced ER! expression following MCAO. ER" immunoreactivity 
was observed in the ischemic core and to a lesser extent in the penumbral region in all treat-
ment groups of rats from the second cohort. Cellular morphology of ER" cells was consistent 
with that of neurons, although no cellular markers were used. No ER" expression was noted in 
the contralateral hemisphere. Both saline and EPO treated Intact rats had similar levels of ER" 
expression in all regions studied (A – H). Compared to Intact rats, both saline and EPO treated 
E2 rats had fewer ER"+ cells, which was most pronounced in the penumbral cortex and stria-
tum (I, L). No significant difference in number of ER"+ cells based on EPO treatment was ob-
served. Scale bars = 50µm.  
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Figure 3.9. E2 rats show reduced EPO-R immunoreactivity in the penumbral cortex and 
striatum. At 24 h after MCAO, brain sections were immunolabeled with EPO-R. Similar to re-
sults from the first cohort of E2 rats, rats from the second cohort treated with E2 beginning at 15 
months (E, F, G, H) also showed reduced EPO-R+ cells compared to Intact rats (A, B, C, D). 
This reduction in EPO-R expression was observed in both penumbral cortex as well as penum-
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bral striatum. Morphology of EPO-R+ cells was consistent with activated astrocytes and micro-
glia. Scale bars = 50µm. 
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Chapter Four 
 
Estrogen supplementation leads to dry eye syndrome in aged female rats  
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Abstract 
Keratoconjunctivitis sicca (KCS) is a leading cause of patient visits to eye care providers. Hor-
mone replacement therapy is associated with an increased incidence of dry eye symptoms and 
KCS, but the mechanism by which this occurs is not known. The current study investigates the 
effects of estrogen supplementation on structure and function of lacrimal and Meibomian glands 
in a clinically relevant animal model. Following 90 days of estrogen supplementation in aged 
female rats, tear volume by a modified Schirmer’s I test and fluorescein tear break up time 
(TBUT)were assessed followed by lacrimal and Meibomian gland excision and histologic evalu-
ation. Hematoxylin and eosin staining as well as immunohistochemistry were performed to ob-
serve structural changes and expression levels of estrogen receptors " and ! in the lacrimal 
and Meibomian glands. Our principle findings include a reduction in tear volume and TBUT in 
estrogen treated rats accompanied by increased connective tissue fibrosis in both extraorbital 
and intraorbital lacrimal glands and reduced acinar lumen in the intraorbital lacrimal glands. 
These functional and structural changes are likely mediated by ER", as estrogen treatment led 
to upregulation of ER" expression in lacrimal and Meibomian glands.   
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Introduction 
Dry eye syndrome, or keratoconjunctivitis sicca (KCS), affects nearly 25 million people in 
the U.S. and is a leading cause of patient visits to both ophthalmologists and optometrists 
(Schaumberg et al., 2001). KCS is associated with an increased risk of corneal infection and in 
severe cases has led to permanent vision loss (Gilbard, 2005). The symptoms associated with 
KCS include ocular dryness, foreign-body sensation or grittiness, pain, burning, photophobia, 
and blurry vision. The discomfort of KCS has been correlated to reduced work capacity (Lemp, 
1998) and increased anxiety and depression (Li et al.). The pathophysiology of KCS is not well 
studied. 
Etiology of keratoconjunctivitis sicca 
A normal tear film is essential for the health of the eye. Enzymes and antibodies in tears, 
namely lysozyme, lactoferrin, B lysin, and immunoglobins A and G serve to protect against ocu-
lar infection (Girgis et al., 2003). Growth factors in tears maintain the corneal integrity. Abnormal 
or insufficient tear film is the result of pathology of one or more structures that produce the lay-
ers of the tear film, of which there are three: a mucin layer produced by goblet cells of the con-
junctival epithelium, an aqueous layer secreted by the lacrimal glands, and a lipid layer pro-
duced by the eyelid Meibomian glands. The mucin layer serves to spread the aqueous layer 
evenly over the ocular surface and represents a very small percentage of the thickness of the 
tear film. The aqueous tear layer, produced by the lacrimal glands, makes up over 90% of the 
thickness of the tear film (Zoukhri, 2006). The lacrimal glands are tubulo-acinar glands and in 
humans are located in the lacrimal fossa of the frontal bone above and toward the temporal as-
pect of the orbit. Meibomian glands are holocrine, tubulo-acinar glands that secrete the most 
anterior tear layer, known as meibum, which contains lipids that serve to prevent evaporation of 
the underlying aqueous layer. The Meibomian glands are located in a single row along both the 
superior and inferior lid margins.  
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Dry eye syndrome is most commonly caused by an inadequate production of the aque-
ous layer by the lacrimal glands (Kecik et al., 1994). Lacrimal gland dysfunction can result from 
infiltration of lymphocytes and overall inflammation, which in some cases occurs as a comorbid 
condition along with another autoimmune disease such as rheumatoid arthritis and/or systemic 
lupus erythematosus (McCartney-Francis et al., 1997, Zoukhri, 2006). When lacrimal gland in-
flammation is accompanied by inflammation and/or enlargement of the salivary glands, the clini-
cal diagnosis is Sjogren’s Syndrome. However, lacrimal gland dysfunction appearing as part of 
Sjogren Syndrome is not as common as lacrimal gland dysfunction without comorbid conditions 
(Chomette et al., 1986, Jabs et al., 1991, Tsubota et al., 2001). Meibomian gland dysfunction 
can also lead to symptoms of KCS. Genetic analysis of human eyelids from normal controls and 
patients with KCS reveal upregulation of genes encoding small proline-rich proteins and S100 
calcium binding proteins, suggesting that keratinization may play a role in Meibomian gland dys-
function and subsequent KCS (Liu et al.). In addition, Meibomian gland dysfunction can be 
caused by altered meibum composition (Mathers et al., 1991) or obstruction of the glands (Driv-
er and Lemp, 1996). Without the presence and proper function of each of the tear film layers, 
dry eye syndrome can result. 
Clinical Diagnosis and Management of KCS 
 Clinical diagnosis of KCS can be determined by the symptoms, but specific tests aide in 
the determination of the severity of the disease. One common test to measure the abundance of 
tears is the Schirmer’s I Test, in which a graded strip of filter paper is placed in the upper palpe-
bral fissure for 5 minutes (Gontier and Fisch, 1976). Tear volume reaching 5 mm or less on the 
filter paper is indicative of dry eye syndrome. In the Schirmer’s test II the nasal mucosa is irritat-
ed by rubbing it with a cotton swab and tear volume is measured. In this test, a tear volume 
equal or less than 15 mm indicates dry eye syndrome. A third test that is commonly used to as-
sess KCS is tear break up time (TBUT) in which fluorescein dye is added to the ocular surface 
to allow visualization of the tear film. The tear film is observed with slit lamp microscopy and the 
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time until the tear film becomes disrupted is measured. Normal TBUT is greater than 10 se-
conds, while TBUT in KCS is commonly less than 5 seconds. TBUT is most useful in the diag-
nosis of evaporative KCS in which tear volume may be normal or increased, but tears evaporate 
quickly due to dysfunction of the lipid layer.  
 Clinical management of KCS can be costly and includes topical lubricants, immunosup-
pressive agents, punctual occlusion, and surgery. For mild to moderate cases of KCS, the first 
line of treatment consists of over-the-counter (OTC) remedies such as artificial tears, humidifi-
ers, and warm compresses. More severe cases of KCS require more aggressive treatment. 
Prescription strength ophthalmic lubricants can provide a more long-lasting effect than OTC arti-
ficial tears (O'Brien and Collum, 2004). In addition, KCS may be treated with ophthalmic anti-
inflammatory medications such as cyclosporine to reduce the inflammation and irritation of the 
conjunctiva. In patients with a definitive autoimmune etiology of KCS, immunesuprressive 
agents, such as corticosteroid drops, can help alleviate symptoms. These drops also promote 
healing in patients with corneal abrasion due to KCS. Finally, if other therapies fail to provide 
relief, surgical treatment is considered. Punctal occlusion is a minor surgical procedure in which 
the punctae are blocked to reduce the tear outflow to the nose, thus allowing tears to remain in 
the eye for a longer duration. Punctal occlusion can be performed by inserting a specially de-
signed ocular device, allowing it be reversible; conversely, the punctae can be occluded perma-
nently with cauterization. Depending on the cause of KCS, more invasive surgeries can be per-
formed to correct the underlying cause. For example, in some stroke patients, the ocular mus-
cles are affected creating lag ophthalmos. This allows increased evaporation of tears and can 
be an underlying cause of KCS. Lag ophthalmos can be corrected by implanting a small gold 
plate in the eyelid that will facilitate the eyelid in closing. KCS caused by evaporative tear loss 
due to eyes that open too widely can be corrected by lateral tarsorrhaphy, in which the lateral 
aspect of the eyelids are sutured together such that the eyes cannot open as widely and close 
more easily (Bodian, 1965).  
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Animal Models of KCS 
 Animal models of KCS have revealed some insights into the multifactorial etiology of the 
disease, but many questions remain. Current models of dry eye syndrome typically involve sin-
gle or multiple doses of drugs such as atropine sulphate (Burgalassi et al., 1999), the preserva-
tive benzalkonium chloride (Lin et al.), T-cell mitogen, concanavalin A (Seo et al.), or botulinum 
toxin B (Hongyok et al., 2009). Yet, despite development of these models, no cure for KCS has 
been developed. To date, no models of KCS have been reported involving the local or systemic 
administration of female gonadal hormones to the aging female rat, despite the fact that the tear 
film is known to be affected by hormone replacement therapy (HRT) (Mathers et al., 1998). In 
the present study, we report a novel model of KCS following chronic systemic administration of 
estradiol (E2) to aging female Sprague-Dawley rats. Although this model could be used to study 
KCS therapeutics, it also provides specific clinical relevance related to the reported increase in 
KCS in women taking HRT. A 2001 report from the Women’s Health Study demonstrated a 
nearly 30% increase of KCS in women taking hormone replacement therapy (HRT), and women 
with prior hysterectomy taking estrogen alone experienced an almost 70% increase in KCS 
compared to non-treated women of the same age (Schaumberg et al., 2001). Moreover, there 
are two reports of estrogen therapy inducing Sjogren’s syndrome, an autoimmune disease that 
targets salivary glands, and the lacrimal gland, leading to KCS (Nagler and Pollack, 2000). The-
se studies show that estrogen is linked to altered tear production. Due to the effects of estrogen 
on the lacrimal gland in women who develop Sjogren’s syndrome, a potential target of estrogen-
ic action is the aqueous tear layer produced by the lacrimal gland. In the present study, we as-
sessed the effects of E2 on tear production and tear break up time in aged female rats. In an 
effort to clarify the mechanism by which estrogen affects tear production, we also examined lac-
rimal and Meibomian glands histologically.   
 
Materials and Methods 
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Chemicals and Animals. Twenty-four female Sprague-Dawley rats, age 15 months, were pur-
chased from Hilltop Animal Laboratory (Scottdale, PA) and housed under 12 h:12 h light/dark 
conditions with food and water provided ad libitum. All chemicals, except where noted, were 
purchased from Sigma-Aldrich (Saint Louis, MO). Isoflurane was purchased from Halocarbon 
(River Edge, NJ). E2 and placebo pellets (1.5mg; 90 d release) were purchased from Innovative 
Research of America (Sarasota, FL). All procedures were in accordance with guidelines set 
forth by the West Virginia University Animal Care and Use Committee.  
Treatment Protocol. Intact rats were subcutaneously implanted with placebo pellets and E2 rats 
received pellets containing 1.5 mg of 17!-estradiol in a 90-day time-release matrix. Both groups 
received treatment until they reached 18 months of age. Serum E2 was measured prior to 
treatment and at 18 months using [I125] radioimmunoassay (U of Virginia Ligand Core, Char-
lottesville, VA).  
Tear Volume Assessment. Tear volume was assessed in rats under isoflurane anesthesia (3 
min, 4% induction, 2% maintenance). Modification of Schirmer’s filter paper strips was as fol-
lows: strips were cut lengthwise in half to reduce width to fit into the rat palpebral fissue and al-
low for more precise measurements of the rat tear volume. The end before graded markings 
began was also removed. Only the halves of the strips containing the graded markings were 
used. Modified Schirmer’s strips were bent at the 2 mm mark and placed with forceps into the 
upper palpebral fissure of the rat for 5 min. After 5 min, test strips were removed and the line on 
the strip where tears reached was recorded. 
Tear Break up Time. Tear break up time (TBUT) was assessed with portable slit lamp with rats 
under isoflurane anesthesia, simultaneous with measurement of tear volume. Following place-
ment of the modified Schirmer’s strip for tear volume assessment, while remaining under isoflu-
rane anesthesia (2% maintenance), rats were positioned laterally to determine TBUT in the con-
tralateral eye. Fluorescein (1.0 µl, 0.25%, OcuSOFT, Richmond, TX) was administered to the rat 
eye followed by three manual blinks. Following the third blink, TBUT was measured with porta-
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ble slit lamp and time to first break in the tear film recorded. This procedure was repeated three 
times with the same eye, and averaged. 
Histology. At 18 months, following functional assessments of tear volume and TBUT, rats were 
transcardially perfused and intraorbital and exorbital lacrimal glands were excised. Eyelids were 
removed for analysis of Meibomian glands. All glands were fixed in 10% buffered formalin over-
night followed by processing for paraffin embedding. After embedding, glands were sectioned at 
8 µm and mounted onto slides. One set of slides each was stained with hematoxylin and eosin, 
immunolabeled with estrogen receptor " and estrogen receptor ! (ER", ER!; abcam, Cam-
bridge, MA). For immunolabeling, mounted sections were treated with 0.3% H2O2-30% metha-
nol in PBS to suppress endogenous peroxidases. Nonspecific binding was blocked using 10% 
horse serum. Sections were incubated in ER" antibody (1:100) and ER! (1:500) overnight at 
4°C. Sections were incubated with biotinylated goat anti-rabbit or horse anti-mouse IgG (Vector 
Laboratories, Burlingame, CA) followed by an avidin-biotin complex process (Vector Laborato-
ries). Finally, sections were exposed to stable 3,3'-diaminobenzidine tetrahydrochloride (DAB). 
Microscopic analysis of hematoxylin and eosin, ER", and ER! stained sections was performed 
using an Olympus AX70 Provis microscope (Center Valley, PA).  
Statistical analysis. Data are presented as mean ± S.E. Statistical significance in measured and 
calculated parameters was determined using one-way ANOVA with Tukey’s post-hoc analyses. 
Level of significance was set at p<0.05. 
 
Results  
Confirmation of distinct treatment groups. Serum E2 levels were measured from blood collected 
prior to randomization to treatment groups and again at time of euthanasia. At 18 months, two 
distinct treatment groups could be differentiated by serum E2 levels with E2 rats having signifi-
cantly elevated serum E2 levels compared to Intact rats (Figure 4.1) 
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Aged rats treated with E2 have reduced tear volume and shorter TBUT. To measure functionali-
ty of tear glands, we studied the tear volume produced by rats using a modified Schirmer’s I 
test. Tear break up time was measured by fluorescein visualization with slit lamp microscopy 
(Figure 4.2). Aged rats receiving E2 had significantly less tear volume  compared to Intact rats 
(7.4 ± 0.58 mm and 15.8 ± 2.1 mm, respectively; p<0.001). TBUT was also altered by estrogen 
treatment with E2 rats having a significant reduction in time to first tear disruption  compared to 
Intact rats (16.4 ± 1.1 sec and 33.7 ± 1.9 sec, respectively; p<0.001) (Figure 4.3).  
E2 alters tissue architecture of lacrimal glands in the aged female rat. In both intraorbital and 
extraorbital lacrimal glands, E2 rats demonstrated increased amounts of connective tissue com-
pared to Intact rats, consistent with fibrosis (Figures 4.3, panels A, B and Figure 4.4, panel B). 
Fibrosis led to disruption of tissue architecture in the intraorbital lacrimal glands of E2 rats, but 
was mostly observed in the interlobular space in the extraorbital lacrimal glands. Extraorbital 
lacrimal glands were also observed to have widened interlobular and intralobular ducts in rats 
receiving E2. No differences between treatment groups were noted in the structure or morphol-
ogy of Meibomian glands of the lower lid. 
Lack of supplemented estrogen was associated with larger acinar lumen and dacryolith for-
mation in the intraorbital lacrimal gland. Hematoxylin and eosin staining revealed stone-like 
structures with lamellar rings within the acinar lumen in some regions of the intraorbital lacrimal 
glands. These lacrimal stones, or dacryoliths also stained darkly with 3,3-diaminobenzidine 
(Figure 4.6, panel C). Intraorbital lacrimal glands from Intact rats showed numerous dacryoliths 
compared to very few and smaller ones in E2 rats (Figure 4.4, panel A). In addition, acinar cells 
of E2 rats appeared to contain more cytoplasm and were more rounded, thereby reducing the 
acinar lumen size compared to less rounded acinar cells and larger lumen size in Intact rats 
(Figure 4.4, panels C,D).  
Estrogen treatment associated with increased ER! expression in tear producing glands. To 
begin to examine the mechanism by which E2 acts in the tear producing glands to reduce tear 
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volume and TBUT, we immunostained glands with ER" antibody. In all glands, ER" immuno-
labeling of cell nuclei was increased in rats receiving E2 compared to Intact rats. In the intraor-
bital lacrimal gland, ER" immunostaining was limited to the gland margin in E2 rats.  
 
Discussion 
Estrogen has been shown to have deleterious effects on tear production in previous 
studies (Nagler and Pollack, 2000). In the present study, we assessed the effects of E2 supple-
mentation on tear production and composition in a clinically relevant animal model. By using 
aged female rats treated with estrogen for 3 months, we created a model of KCS arising from 
HRT. In this model, we assessed both functional and structural/molecular aspects of tear pro-
duction including tear volume, TBUT, gland structure, and ER expression. This study showed 
for the first time that chronic systemic E2 supplementation alters lacrimal and Meibomian gland 
structure and function in aged female rats, and these changes are associated with increased 
ER" expression.  
Specifically, using a modification of the Schirmer’s I test, we measured tear volume in In-
tact and E2 treated aged female rats and found that chronic E2 supplementation leads to re-
duced tear volume. TBUT was measured with slit lamp microscopy and revealed that tear film 
undergoes faster evaporative loss in rats receiving E2. This reduced TBUT could result from 
either inadequate lipid layer production, thus allowing evaporative loss, or an overall reduction in 
aqueous tear component. Future studies will focus on specific effects of estrogen on tear com-
position. 
To more fully evaluate estrogenic effects on tear producing glands, we removed glands 
from rats and processed them for histology. Upon examination, lacrimal gland sections revealed 
several important differences between Intact and E2 rats: 1) increased connective tissue fibrosis 
in E2 rat lacrimal glands accompanied by widened interlobular and intralobular spaces in the 
extraorbital glands 2) more rounded acinar cells and reduced acinar lumen size in intraorbital 
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lacrimal glands of E2 rats, and 3) numerous lacrimal dacryoliths in intraorbital glands of rats 
lacking supplemented E2. Connective tissue fibrosis in both intraorbital and extraorbital lacrimal 
glands of E2 rats was also associated with disruption of the normal tissue architecture and may 
be a contributing factor to the reduced functionality of the glands. In addition, the smaller lumen 
size of acinar structures in E2 rats may increase likelihood of obstruction and/or reduce the out-
flow of secretions, thereby contributing to reduced tear volume. In addition to lumen size, acina 
in both Intact and E2 rats contained protein-rich material that stained more darkly in E2 rats. 
Darkly stained material within the acinar lumen may indicate greater protein content, but further 
analysis of tear composition would need to be conducted to verify this hypothesis. Lastly, the 
presence of numerous dacryoliths in the intraorbital lacrimal glands of Intact rats suggests an 
estrogen-related inhibition of dacryolith formation. Previous studies suggest patients with symp-
tomatic dacryolithiasis are more likely to be female (59.1%) and over age 70 years, therefore 
postmenopausal (Repp et al., 2009), thus supporting the notion that female gonadal hormones 
play a role in inhibiting dacryolith formation. However, dacryolith presence was not associated 
with reduced function of tears in the present study as Intact rats had significantly higher tear 
volume and TBUT compared to E2 rats. 
Importantly, no significant inflammatory cell infiltrates were observed in glands from E2 
rats. Due to the reported cases of HRT leading to the development of Sjogren’s syndrome, one 
hypothesis for the deleterious actions of estrogen in the lacrimal and Meibomian glands is 
through inflammatory disruption of normal cell function and tissue structure (Toda et al., 1999, 
Niederkorn et al., 2006, Zoukhri, 2006).  Our results do not support this hypothesis of estrogenic 
action in lacrimal and Meibomian glands of our aged female rat model; however, additional stud-
ies, such as mRNA quantification of inflammatory cytokines, would be useful to rule it out.  
In order to determine how estrogen mediates its actions on the tear producing glands, 
we performed immunohistochemistry on sections from lacrimal and Meibomian glands of E2 
and Intact rats. Previous report have demonstrated the presence of ER" in lacrimal and Meibo-
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mian glands of young adult rats (Spelsberg et al., 2004, Richards and Sullivan, 2009). In the 
present study, we found ER" immunoreactivity in the lacrimal and Meibomian glands of aged 
female rats and we show that ER" expression is upregulated by chronic E2 supplementation. 
We also confirmed a lack of immunostaining of ER! in lacrimal and Meibomian glands (data not 
shown), as has been reported previously. Together with tear volume and TBUT data, these re-
sults support the notion that E2 actions in the tear producing glands are mediated through ER". 
The functional consequences of ER" signaling in the tear glands are unknown as estrogen re-
sponse elements are found on many genes that may affect tear gland structure and/or tear pro-
duction. Specifically, in the mammary gland, estrogen has been shown to regulate expression of 
extracellular matrix (ECM) proteins and integrins (Haslam and Woodward, 2003), but estrogenic 
effects on ECM of lacrimal and Meibomian glands have not been studied to date. Considering 
our findings of increased connective tissue fibrosis in E2 rats, estrogen-mediated changes in 
ECM proteins may play a role in those structural changes observed in our model. 
The findings presented here are an initial attempt to understand lacrimal and Meibomian 
gland structure and function in an aged, female, estrogen treated rat model of KCS. However, 
there are several caveats to the present study. A potentially confounding variable in the tear 
volume and TBUT assessments is time spent under anesthesia. We attempted to control for 
rats not closing their eyes during anesthetic induction by standardizing the induction time to 3 
min, nevertheless, differences in evaporative tear loss prior to the assessments may have af-
fected our results. Also, the form of E2 supplementation used in this study is unlike commonly 
used hormone replacement therapy in women. Clinically prescribed conjugated equine estrogen 
is a mixture of several estrogens, with the most common preparation containing estrone sulfate, 
equilin sulfate, and equilenin sulfate. We administered the most active form of estrogen, 17!-
estradiol in time-release pellets. However, time-release pellets do not provide a constant dose 
of E2. Upon subcutaneous implantation of E2 pellets, serum E2 levels increase rapidly followed 
by a slow decline in hormone level, which differs from the more constant hormone levels 
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achieved by oral supplementation in women. Despite these caveats, the results presented here 
offer a beginning towards a more full understanding of the role of E2 in the lacrimal and Meibo-
mian glands. 
 
Summary  
In the year 2000, the prevalence of dry eye symptoms in women was estimated to be 
16.7% in the Beaver Dam Eye Study Cohort (Moss et al., 2000). Data from the Women’s Health 
Study implicates HRT, particularly estrogen therapy alone, in the development of dry eye syn-
drome in postmenopausal women (Schaumberg et al., 2001). The effects of estrogen on the 
lacrimal and Meibomian glands are largely unknown and unstudied. Due to the health and eco-
nomic burden of dry eye syndrome, a more full understanding of this disease and its etiology 
should be the focus of ophthalmic research, particularly in aged animal models that mimic KCS 
arising from HRT. 
In the present study, we showed for the first time that aged rats treated chronically with 
E2 have reduced tear volume and shorter TBUT compared to normally aging female rats. We 
also demonstrated specific structural changes in the lacrimal glands of rats receiving E2 includ-
ing increased fibrosis (which disrupted normal tissue architecture in some areas) larger acinar 
cells, and reduced acinar lumen size. We also noted the presence of numerous dacryoliths in 
Intact animals which were either not present or much smaller in size in E2 rats. Finally, we per-
formed immunostaining for both ER" and ER! in tear producing glands of both aged Intact and 
aged E2 treated rats. ER! immunostaining did not reveal ER! expression in any of the tear 
glands. Conversely, we observed ER" expression in all tear glands which was upregulated in all 
tear producing glands of rats receiving E2, suggesting that E2-mediated effects on the tear 
glands are mediated through ER". Future studies on the effects of estrogen in KCS will focus 
on the mechanism of estrogenic action - identificantion of specific proteins that are altered by E2 
and that lead to the structural and functional changes we observed in the tear glands. 
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Figure 4.1. Significant difference in serum E2 levels between E2 and placebo treated rats. 
Serum E2 levels of rats prior to randomization at 15 months of age (Pre) and two weeks before 
gland excision, at 18 months of age (Post). Rats treated with pellets containing 17!-estradiol 
had significantly higher serum E2 levels at 18 months compared to rats administered placebo 
pellets. *p<0.05 compared to placebo treated rats using one-way ANOVA with Tukey’s post hoc 
analysis.  
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Figure 4.2. Modified Schirmer’s I test and tear breakup time in the anesthestized rat. (A) A 
modified Schirmer’s filter paper strip fits more easily in the upper palpebral fissure of the Spra-
gue-Dawley rat and allows for improved precision in quantifying tear volume in the rat. (B) A 
portable slit lamp was used to determine tear break up time in the anesthetized animal. Follow-
ing administration of fluorescein sodium (0.25%), one researcher manually blinks the eye three 
times and then aides in holding it open while tear break up time is measured by a second re-
searcher. 
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Figure 4.3. Estrogen treatment leads to reduced tear volume and lower tear break up time 
in aged female rats. (A) Tear volume was measured in 18 month old female rats during 3 
months of E2 or placebo supplementation. Intact rats had significantly higher tear volume as 
measured by the modified Schirmer’s I test compared to E2 rats. (B) Tear break up time was 
also measured in rats receiving placebo or E2 treatment using fluorescein sodium (0.25%). 
Time to first break up of tear film, as observed with slit lamp microscopy, was significantly higher 
in Intact rats compared to E2 rats. #p<0.001 compared to E2 rats using one-way ANOVA with 
Tukey’s post hoc analysis. 
 
 
  
# 
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Figure 4.4. Chronic estrogen supplementation leads to alterations in tissue architecture 
of extraorbital lacrimal glands in aged female rats. At 18 months, following 3 months of E2 
or placebo supplementation, extraorbital lacrimal glands were excised and prepared for hema-
toxylin and eosin staining. (A, B) Compared to Intact rats, E2 rats had increased peri-vascular 
connective tissue, indicating fibrosis (*). (C, D) E2 rats also demonstrated widened interlobular 
(arrowheads) and interlobular (arrows) spaces in the extraorbital lacrimal gland. Scale bars = 
100µm. 
 
  
111 
 
Figure 4.5. Intraorbital lacrimal glands of aged rats without estrogen supplementation 
contain dacryoliths and exhibit larger acinar lumen. Intraorbital lacrimal glands from 18 
month old female rats were examined following 3 months of E2 or placebo treatment. All rats 
exhibited protein-rich material within the acinar lumen, which stained more darkly in glands from 
E2 rats (B, D). Intact rats (A) exhibited larger and more abundant intra-lumenal dacryoliths (d), 
as well as larger acinar lumen (C) compared to E2 rats (B, D). Similar to findings in the extraor-
bital lacrimal glands, E2 rats exhibited greater degree of connective tissue fibrosis and disrup-
tion of the acinar structures in the intraorbital lacrimal glands (B) compared to Intact rats (A). 
Scale bars A, B = 100µm; scale bars C, D = 50µm. 
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Figure 4.6. Hematoxylin and eosin staining of lower lid margin showing Meibomian 
glands in Intact and E2 rats. No structural or morphological differences between Intact and E2 
groups were observed in Meibomian glands of the lower lid margin. Scale bars = 100µm. 
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Figure 4.7. Estrogen receptor ! expression is increased in the eye glands of aged female 
rats receiving E2 supplementation. ER" expression was measured in extraorbital lacrimal 
glands, intraorbital lacrimal glands, and Meibomian glands of aged female rats following 3 
months of E2 or placebo treatment. ER" immunostaining was observed in the nuclei of some 
cells in all glands of both Intact (A, C, E) and E2 (B, D, F) rats (arrows). However, in E2 rats, the 
number of cells staining for ER" was increased in all glands studied. In the intraorbital lacrimal 
glands of E2 rats, ER" expression was limited to the gland margin (D). Intraorbital lacrimal 
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glands of Intact rats contained darkly staining dacryoliths, which were fewer and smaller in 
glands from E2 rats (C). Scale bars A – D = 100µm; scale bars E, F = 50µm. 
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Chapter Five  
 
Hippocampal-dependent memory in aged rats following middle cerebral artery occlusion 
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Abstract 
Current experimental models of stroke commonly utilize young adult rats and involve suture oc-
clusion of the middle cerebral artery. More clinically relevant models have recently been devel-
oped that involve aged rats and a fibrin blood clot occlusion of the middle cerebral artery 
(MCAO). Cognitive and behavioral outcome from experimental stroke are poorly understood, 
particularly in the recently developed models. In the present study, we assessed hippocampal-
dependent memory using the 8-arm radial maze in young adult and aged female rats following 
middle cerebral artery occlusion with fibrin clot and tissue plasminogen activator reperfusion. 
Aged rats required greater number of sessions to become trained and had increased trial dura-
tion, suggesting reduced locomotor activity. Although baseline differences in reference and 
working memory errors were observed, they did not reach significance. Following MCAO, no 
significant differences were found in reference or working memory errors between young adult 
and aged rats.   
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Introduction 
 Although the middle cerebral artery does not supply the hippocampus, cells of the hip-
pocampus can undergo apoptosis following ischemia/reperfusion injury due to excitotoxic dam-
age from the necrotic death and release of glutamate from surrounding cells (Yang et al., 2001, 
Xu et al., 2007). Damage to the hippocampus is of significant concern following stroke due to its 
relevance to the behavioral outcome from stroke. Animal models of stroke have undergone sig-
nificant development and improvement since research began in the field (Kudo et al., 1982, 
Kaneko et al., 1985, Bederson et al., 1986, Dinapoli et al., 2006). The most common models 
used today involve insertion of a modified suture or fibrin-rich blood clot into the proximal middle 
cerebral artery, and are referred to as transient or permanent middle cerebral artery occlusion 
(MCAO). In both suture and fibrin clot models, reperfusion can be achieved by suture removal 
or administration of a thrombolytic agent. These models have been shown to produce consistent 
infarct volumes and functional impairment. However, it is unknown if these newer models of 
MCAO have effects on the hippocampus. Of particular interest are experimental stroke models 
that utilize aged animals, which typically have larger infarcts, thus increasing the chance of hip-
pocampal damage (Dinapoli et al., 2006). 
 The hippocampus is involved in short term memory, memory consolidation, and spatial 
navigation. Functional assessment of the hippocampus in animal models of brain injury typically 
relies on hippocampal-dependent navigation, including both working and reference memory. 
Various types of mazes are often used and depending on their design and use, can test either 
working or reference memory or both. One commonly used task is the 8-arm radial maze in 
which rats can be trained to search the arms for food rewards (Toumane et al., 1988). Visual 
cues in the maze room allow for the assessment of reference memory. With some arms of the 
maze baited and others not baited, food-restricted rats rely on reference memory to navigate to 
arms containing food rewards. Working memory is tested by counting the times rats re-enter an 
arm where a food reward was previously eaten during the same trial. 
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 The focus of the present study was to determine the effects of experimental stroke on 
hippocampal-dependent memory using the 8-arm radial maze in young adult and aged female 
rats. We used the 8-arm radial maze to evaluate both reference and working memory errors one 
week after reversible occlusion of the middle cerebral artery with fibrin clot. Results demonstrate 
that aged animals require more training sessions to become trained and aged rats take longer 
to complete the maze task. Despite these training differences, young adult and aged female rats 
do not exhibit hippocampal-dependent memory losses following MCAO.  
 
Materials and Methods 
Chemicals and Animals. Ketamine and xylazine were purchased from Sigma (St. Louis, MO). 
Human recombinant tissue plasminogen activator (tPA) was gifted from Genentech (South San 
Francisco, CA). Thirty-six female Sprague-Dawley rats (3 months (N=24) and 18 months 
(N=12)) were purchased from Hilltop Animal Laboratory (Scottdale, PA) and housed under 
12h:12h light/dark conditions with water provided ad libitum and food restricted to maintain rats 
at 85% of their ad libitum weight. All procedures were in accordance with guidelines set forth by 
the West Virginia University Animal Care and Use Committee.  
Food restriction and radial maze training. During a one-week acclimation to the training room, 
rats were fed ad libitum and at the end of the week their ad libitum weight was recorded. The 
following day food was restricted to 10 g/day including several food rewards (Froot Loops cere-
al, Kellogg’s, Battle Creek, MI), and continued as such until rats reached 85% of their ad libitum 
feeding weight. Throughout training and testing, rats were maintained at 85% of their ad libitum 
feeding weight. Rats were acclimated to the 8-arm radial maze (60x10x12 cm high, elevated 70 
cm above the floor) in three 10 min trials held on consecutive days. Acclimation trials consisted 
of rats being placed in the center of the maze under plexiglass cover for 30 sec in groups of 2 or 
3 rats. Cover was lifted and rats were given 10 min to freely explore the maze and eat food re-
wards placed throughout the maze. Training began on the day following the last acclimation trial 
119 
and consisted of two trials per day. Training trials used the same four baited arms each time 
and trials ended when all food rewards were eaten or after 5 min. Total arm entries and total 
trial duration were recorded along with reference and working memory errors. Training was con-
sidered complete when rats achieved zero working memory errors and an average of less than 
one reference memory error in five consecutive sessions. Rats that failed to become trained 
within 50 training sessions were excluded from further analysis. Testing trials were performed 
following one week of recovery from MCAO and occurred once daily for five consecutive days.  
Middle cerebray artery occlusion. Upon training completion, rats underwent a transient ischemic 
stroke by occlusion of the right middle cerebral artery with tissue plasminogen activator (tPA; 
5mg/kg, i.v.) reperfusion under ketamine and xylazine anesthesia (5mg/kg and 10 mg/kg, re-
spectively), as previously described (Dinapoli et al., 2006). Ischemia was defined by a perfusion 
drop across the MCA territory of greater than 80% as determined by laser Doppler measure-
ment of cerebral blood flow and successful reperfusion was denoted as a return to greater than 
80% of baseline perfusion rate by 30min after tPA administration.  Rats not achieving these 
standards for depth and duration of ischemia as well as reperfusion were excluded from the 
study. Sham operation involved similar procedures except that no clot was inserted. At 24h after 
MCAO, functional assessment was measured by an investigator blinded to the treatment using 
the modified Neurological Severity Score (mNSS) (Li et al., 2002). Following one week of re-
covery, rats were tested in the 8-arm radial maze once daily for five consecutive days.  
Functional assessment. At 24 h after MCAO, rats were assessed for functional impairment us-
ing the modified Neurological Severity Score. This assessment consisted of five subtests to 
measure voluntary motor function, balance, and motor reflexes. Scores range from 1 to 17 with 
higher scores indicating more severe functional impairment (Li et al., 2000).  
 
Results 
120 
Aged rats had longer trial duration and required more sessions to become trained. Despite the 
lack of functional impairment of aged rats before undergoing MCAO, the per-trial duration of 
aged rats was significantly higher compared to young adult rats. By the 25th session, the aver-
age per trial duration of young adult rats was 75 sec compared to 126 sec in the aged rat group. 
The number of training sessions for rats to achieve zero working memory errors and an average 
of less than one reference memory error in five consecutive sessions was also increased in the 
aged rat group, but not significantly. By the end of the 25th training session, the majority of 
young adult rats (92%) had achieved this level of training; however, many more aged rats were 
not yet trained by the 25th session and 16% of aged rats had not reached trained status by the 
50th training session, and were excluded from further analysis.  
Aged rats had greater functional impairment following MCAO. Previous reports from our lab and 
others have demonstrated that aged rats experience worsened functional impairment following 
MCAO compared to young adult counterparts. In the present study, aged rats had an average 
composite mNSS of 7 at 24 h after MCAO, while young adult rats had an average composite 
score of 4, indicating significantly greater degree of functional disability in aged rats following 
MCAO (p=0.017).  
Frequency of reference and working memory errors not significantly altered in aged rats. Follow-
ing one week of recovery from MCAO, rats were tested in the 8-arm radial maze in one session 
per day for five consecutive days. Reference and working memory errors were recorded. Data 
demonstrate that there is no significant difference between frequency of reference memory er-
rors in young adult or aged rats subjected to MCAO compared to age-matched or sham-
operated rats. Although a trend towards higher reference memory errors was observed in aged 
rats following MCAO compared to young adult rats following MCAO, data did not reach signifi-
cance. Likewise, no significant effect of age was measured in frequency of working memory er-
rors following MCAO.  
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Discussion 
This study examined the hippocampal-dependent memory in young adult and aged fe-
male rats prior to and following one week of recovery from MCAO or sham surgery. Our results 
show that aged rats take longer to acquire stable performance in the 8-arm radial maze and a 
significantly greater number of aged rats do not achieve trained status within 50 training ses-
sions, compared to young adult rats. The present study also demonstrated for the first time that 
current fibrin clot models of transient MCAO produce no measureable differences in reference 
or working memory errors in young adult and aged female rats compared to age-matched 
sham-operated rats. Similarly, no significant differences between young adult and aged rats un-
dergoing MCAO were found. Although histologic confirmation of an absence of hippocampal 
damage was not performed, behavioral analysis with the 8-arm radial maze demonstrated no 
significant differences in post-ischemic performance based on age or MCAO.  
There are several important caveats to consider regarding these results. Although nec-
essary to ensure motivation in training, calorie restriction and decreased body weight undoubt-
edly affect the neurologic sequelae of experimental stroke. Reports indicate that calorie-
restricted rats perform better on cognitive and motor tasks (Means et al., 1993), although the 
effects of calorie restriction in aged rats following stroke has not been studied to date. An addi-
tional source of neuroprotection in the present study was the anesthetic agent used, which was 
ketamine. At the time the present study was conducted, few reports existed regarding the neu-
roprotective effects of ketamine. However, more recently accumulating evidence suggests that 
ketamine acts through several mechanisms to reduce neuronal injury following insult (Schifilliti 
et al., , Zhang et al., 2006b). Specifically, studies have demonstrated that ketamine can inhibit 
N-methyl-D-aspartate (NMDA) receptor, which reduces excitotoxic cell death, an important 
component of the secondary phase of injury following acute ischemic stroke (Himmelseher et 
al., 1996). Ketamine can also reduce apoptotic cell death through signaling pathways that result 
in attenuated levels of pro-apoptotic proteins such as Bax (Engelhard et al., 2003). Lastly, neu-
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roprotection by ketamine is thought to involve a reduction in post-injury inflammation as meas-
ured by cytokines tumor necrosis factor ", interleukin-6, and interleukin-8 (Kawasaki et al., 
1999). For these reasons, ketamine is no longer used in studies involving neural injury. 
 
Summary 
The present study offers interesting data regarding the hippocampal-dependent memory 
in young adult and aged rats prior to and following MCAO. Future studies could improve on this 
data set by including additional behavioral assessments to more fully profile the cognitive differ-
ences between young adult and aged rats before and after experimental stroke. Of particular 
interest would be passive avoidance test and Morris water maze, both of which require hippo-
campal-dependent memory. To more fully understand basal and post-ischemic locomotor differ-
ences between young adult and aged rats, the open-field test would be informative. In addition, 
histologic examination of the brain would provide invaluable information as to whether hippo-
campal neurons are affected by experimental stroke. Specific stains, such as Fluoro-Jade B, 
which labels degenerating neurons would allow visualization of hippocampal damage. Although 
the fibrin clot model is a clinically relevant model of stroke, a greater understanding of experi-
mental stroke models would come from studies involving multiple models, both transient and 
permanent occlusion with both suture and fibrin clot. In summary, information regarding the 
cognitive and behavioral assessment of rats following experimental stroke is lacking in the litera-
ture, but has significant clinical relevance. In order to obtain meaningful results from experi-
ments involving stroke, a clear understanding of all facets of the model that is used must be ac-
quired. 
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Figure 5.1. Aged rats require longer trial duration. Trial duration was measured as time to 
collect all food rewards with 5 min as the maximum time allowed. During 50 training sessions, 
aged rats required significantly more time to complete trials compared to young adult rats. 
*p<0.05 compared to young adult rats using one-way repeated measures ANOVA. 
 
 
  
* 
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Figure 5.2.  No significant differences between young adult and aged rats in number of 
reference or working memory errors during training. Although aged rats began training with 
similar numbers of reference (A) and working (B) memory errors, young adult rats had reduced 
number of both error types by the tenth training session, although the difference did not reach 
significance. By the 50th training session significantly more aged rats (16%) than young adult 
rats (4%) had not reached the required level of training to continue in the experiment. 
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Figure 5.3. Aged rats have greater functional impairment following MCAO. Functional im-
pairment was assessed at 24 h after MCAO using the modified Neurological Severity Score 
(mNSS), a commonly used battery of motor, balance, and reflexes in stroke research. Con-
sistent with previous reports, aged rats in this study had higher composite mNSS score indicat-
ing more severe functional impairment following MCAO compared to young adult rats. *p<0.05 
compared to young adult rats using one-way ANOVA with Tukey’s post hoc analysis.  
* 
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Figure 5.4. No difference based on age or MCAO in frequency of reference or working 
memory errors. Following MCAO, young adult and aged rats showed no significant differences 
in frequency of reference (A) or working (B) memory errors compared to sham-operated rats. 
Also, no significant differences were measured between young adult and aged rats following 
MCAO, although a trend towards higher reference memory errors was observed in aged rats 
following MCAO. 
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Chapter Six 
 
Conclusions and Future Directions 
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Introduction 
The dissertation research presented here encompasses several components of the ef-
fects of estrogen in an aged female rat model. This research has clinical relevance and im-
portance, as demonstrated by the fact that in the year 2000, an estimated 10 million women 
were taking HRT for the management of menopausal symptoms. HRT is known to be an effec-
tive and cost efficient therapy for menopausal symptoms which can include hot flashes, fatigue, 
hair loss, sleep disturbance, vaginal dryness, weight gain, cognitive disturbance, loss of libido, 
headaches, joint pain, depression, and anxiety, among others. Since the release of reports from 
the WHI, FDA guidelines for the use of HRT have been altered to recommend that patients take 
the lowest effective dose for the shortest amount of time, potentially leading to undertreatment 
of menopausal symptoms (Bren, 2003). Clinical studies have demonstrated that not all effects of 
HRT or estrogen alone are beneficial. Estrogen has been shown to increase the incidence of 
stroke in postmenopausal women (Wassertheil-Smoller et al., 2003, Anderson et al., 2004), alt-
hough a recent randomized controlled clinical trial demonstrates that increased stroke incidence 
does not persist following termination of HRT (LaCroix et al.). In addition, HRT is associated 
with tear gland dysfunction resulting in dry eye syndrome, a painful condition that is often under-
treated. These effects of estrogen therapy were the focus of the dissertation research presented 
here.  
 
Estrogen and Ischemic Brain Injury 
In our first study, we examined the role of chronic estrogen supplementation on experi-
mental stroke injury in young adult and aged female rats. We hypothesized that differences in 
estrogenic action in ischemic brain injury between young adult animal models and postmeno-
pausal women resulted from age-related alterations in estrogenic action. Evidence from numer-
ous studies indicates that estrogenic actions and receptors in the brain are affected by age. 
Specifically, there are changes in splice variants of ER" with age (Ishunina and Swaab, 2008), 
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differential effects of estrogen on abundance of specific cell types with age, and altered effects 
of estrogen on post-ischemic cognitive performance with age. Using a clinically relevant animal 
model of E2 supplementation and experimental stroke, we demonstrated for the first time wors-
ened stroke injury and increased mortality with E2 treatment in aged animals following MCAO, 
which parallel the findings of the WHI (Wassertheil-Smoller et al., 2003). The importance of an 
animal model that accurately represents the clinical problem cannot be overstated, and the 
model described here provides an important first step in addressing that issue. 
The next step in this research is to identify a mechanism by which estrogen acts in the 
aged, injured brain. To that end, we explored a number of potential candidates, and revealed 
important new information that contributed to the development of an evidence-based hypothesis 
for the mechanism of estrogenic action. One pathway that we explored has been previously im-
plicated in age-related differences in stroke injury. Previous investigations of the JAK2/STAT3 
pathway in our lab demonstrate that aged rats experience a truncated activation of STAT3 com-
pared to young adult counterparts (Dinapoli et al. 2010). STAT3 is an important transcription 
factor that targets several genes important to recovery from stroke, and was a plausible candi-
date for age-related differences in estrogenic activity in the post-ischemic brain. In addition, 
suppressor of cytokine signaling 3, an inhibitor of the pathway and attenuator of reactive astro-
gliosis was previously shown to be upregulated in aged animals (Dinapoli et al. 2010). Based on 
this foundation of age-related alterations in the JAK2/STAT3 pathway, we hypothesized that es-
trogen may also exert its age-related effects through JAK2/STAT3. To test this hypothesis, we 
measured protein levels of total and phosphorylated STAT3 in the ischemic cortex and striatum 
of our E2 rats in comparison to Intact and OVX rats. We did not find any significant differences 
based on E2 treatment. We also looked at mRNA levels of JAK2 and STAT3 and found no es-
trogen-related effect. Finally, we used a JAK/STAT array to more fully evaluate estrogenic ef-
fects on post-ischemic JAK/STAT pathways. 
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Data from the JAK/STAT array used with our first cohort of animals showed that E2-
mediated exacerbation of stroke injury was accompanied by downregulation of EPO-R mRNA. 
We confirmed that E2 rats also had reduced expression of EPO-R protein in the penumbral re-
gions of the post-ischemic brain. Using immunohistochemical techniques we also observed re-
duced expression of ER" in the ischemic hemisphere of E2-treated rats. These findings led to 
the design of a second study in which we attempted to rescue E2-mediated exacerbation of 
stroke injury with acute treatment with EPO, a known neuroprotectant. This study required the 
use of a different model of MCAO as EPO-tPA interactions have been suggested to lead to in-
creased post-ischemic mortality and are poorly understood. Using the suture occlusion model of 
MCAO, we hypothesized that if estrogenic effects on EPO-R were responsible for increased in-
farct size in E2 treated rats, acute treatment with EPO would compensate for reduced EPO-R 
expression and attenuate the extent of estrogen-mediated injury. Our hypothesis was supported 
by the data, which showed a reduction in total infarct volume in rats receiving EPO. EPO treat-
ment also reduced disruption of tissue architecture and petechial formation within the ischemic 
parencyma. In this second cohort, we also confirmed the estrogen-mediated reduction in EPO-R 
protein expression in the penumbral region as well as estrogen-mediated attenuation of ER" in 
the ischemic hemisphere that had been observed in the first cohort of rats.   
Taken together, our findings support a proposed mechanism of estrogenic action in the 
post-ischemic brain where chronic estrogen supplementation leads to reduced ER" expression 
which, in turn, reduces EPO-R expression and results in exacerbated ischemic injury. In this 
proposed mechanism, and supported by our data, it is the EPO/EPO-R system, rather than es-
trogen directly that confers neuroprotection and is altered by chronic E2 treatment. However, 
this proposed model of estrogenic action in the post-ischemic brain raises additional questions. 
Specifically, is the EPO/EPO-R system altered prior to ischemic injury or do estrogen-mediated 
changes only affect the post-ischemic EPO/EPO-R response? Experiments looking at ER", 
EPO, and EPO-R in sham-operated and naïve animals as well as in cultured cell lines would 
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provide valuable information regarding basal effects of estrogen on the EPO/EPO-R system in 
the brain and in specific cell types.  
Next, how exactly does estrogen regulate basal or post-ischemic EPO-R expression? If 
estrogen only affects post-ischemic EPO-R expression, rather than basal levels, the likely an-
swer involves hypoxia-inducible factor 1 (HIF-1), the transcription factor responsible for hypoxia-
mediated upregulation in EPO-R. HIF-1 has two subunits, both constitutively expressed in the 
cell. However, one subunit, HIF-1", is ubiquitin tagged for proteasomal degradation by the en-
zyme HIF prolyl-hydroxylase, which requires oxygen as a co-substrate. When oxygen becomes 
scarce, HIF prolyl-hydrolase cannot ubiquitinate HIF-1", thus it is not degraded and can then 
associate with HIF-1! to form an activated transcription factor that targets genes important to 
survival in hypoxic conditions, such as EPO-R. Experiments to test whether E2 acts through 
HIF-1 would involve protein and mRNA quantification of that pathway in cells or animals treated 
with estrogen. If inhibitors of HIF-1 transciptional regulation of EPO-R eliminate the estrogenic 
effects on EPO-R, that would provide further support of the involvement of HIF-1 in estrogenic 
downregulation of EPO-R.  
Lastly, if estrogen acts through ER" to alter EPO-R in aged female rats leading to in-
creases in post-ischemic infarct size, how does estrogen provide neuroprotection in young adult 
animals? This question poses the greatest quandary since no known age-related differences in 
ER" or the EPO/EPO-R system in the brain have been reported. Future investigations of the 
mechanisms of estrogenic actions should involve young adult counterparts in order to gain in-
sight into the age-dependent activity of estrogen in the brain. 
 
Estrogenic Effects on Tear Producing Glands 
The effects of estrogen on the lacrimal and Meibomian glands are poorly understood. 
Data from the Women’s Health Study implicates HRT, particularly estrogen therapy alone, in the 
development of dry eye syndrome in postmenopausal women (Schaumberg et al., 2001). Ob-
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servational data support a role for female gonadal hormones in the tear producing glands. In the 
year 2000, the prevalence of dry eye symptoms in women was estimated to be 16.7% com-
pared to 11.4% in men (Moss et al., 2000). Dry eye syndrome, or keratoconjunctivitis sicca 
(KCS), leads to significant distress and can result in severe consequences such as corneal 
abrasion or visual impairment. Due to the lack of understanding of the etiology and pathophysi-
ology of dry eye syndrome, this disease should be the focus of continuing ophthalmic research. 
Of specific concern are the effects of estrogen on the structure and function of tear glands, 
which has been shown to be deleterious and lead to dysfunction and the development of KCS.  
In the third study described here, we investigated the lacrimal and Meibomian glands of 
rats from our second cohort of estrogen treated rats. Two weeks prior to MCAO, tear gland 
function of E2 and Intact rats was assessed using two commonly used clinical tests: the 
Schirmer’s I test and fluorescein tear break-up time (TBUT). We describe a modification of the 
Schirmer’s I test to adapt it to the smaller tear volumes and eye structure of the rat. Using the 
modified Schirmer’s I test, we found that estrogen treated aged rats had reduced tear volume 
compared to Intact aged rats.  TBUT was also different between the groups with E2 rats show-
ing reduced time to first break in the tear film.  
In the second part of this study, we examined the tear glands histologically. Unlike hu-
mans, rats have both intraorbital and extraorbital lacrimal glands. Following sacrifice at the end 
of our experiments involving estrogenic effects on stroke, we excised both lacrimal glands and 
Meibomian glands on the side contralateral to the MCAO surgery. The lacrimal glands in hu-
mans receive blood supply from the ophthalmic artery, a branch off the proximal middle cerebral 
artery. In order to avoid erroneous conclusions based on restricted blood flow, we did not use 
glands from the side ipsilateral to MCAO surgery. From histologic evaluation of extraorbital and 
intraorbital lacrimal glands as well as Meibomian glands of the lower lid, we demonstrated spe-
cific structural changes in the lacrimal glands of rats receiving E2. Changes in lacrimal glands 
included increased fibrosis, which disrupted normal tissue architecture in some areas. We noted 
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changes in the structure of acini of the intraorbital lacrimal glands with E2 rats displaying larger 
acinar cells and reduced acinar lumen size. We also noted the presence of numerous dacryo-
liths in Intact animals which were either not present or much smaller in size in E2 rats.  
The last experiment of this study involved immunostaining for both ER" and ER! in tear 
producing glands of both aged Intact and aged E2 treated rats. ER! immunostaining did not re-
veal ER! expression in any of the tear glands, which was consistent with previous reports in 
healthy young adult rats not receiving hormonal therapy (Spelsberg et al., 2004). We did, how-
ever, observe ER" expression in all tear glands, which was upregulated in glands of rats receiv-
ing E2. This data suggests that E2-mediated effects on the tear glands are mediated through 
ER", rather than ER!. However, the exact mechanism by which estrogen alters tear gland 
structure and function remains unclear. Specific pathways and proteins that are altered by E2 
and that lead to the structural and functional changes must be identified. Based on our finding of 
increased connective tissue fibrosis in glands from estrogen-treated rats, proteins involved in 
extracellular matrix remodeling are likely candidates for influence by estrogen. Questions re-
main regarding age-related differences in the effects of estrogen on tear producing glands. Fu-
ture studies to investigate the mechanism should include young adult counterparts in order to 
elucidate differences between young adult and aged rats. 
 
Hippocampal-dependent memory in an aged animal model of stroke 
The final study presented in this dissertation research sought to characterize the behav-
ioral outcomes from our model of experimental stroke. Behavioral evaluation of current models 
of stroke is poorly defined. Functional consequences of stroke, however, are of utmost im-
portance and should be a main outcome measure in all stroke studies, as outlined in the STAIR 
recommendations (Fisher et al., 2009). Our lab has been on the forefront of developing a clini-
cally relevant model of transient ischemic stroke. Specifically, our model utilizes fibrin clot col-
lected from a blood donor rat and monitors depth of ischemia throughout the procedure. By us-
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ing a fibrin clot, we permit reperfusion of the MCA by administering tPA, similar to the clinical 
situation. Coupled with the use of aged animals, this model of transient embolic occlusion of the 
middle cerebral artery parallels the clinical scenario of stroke unlike any other model used in the 
field (Dinapoli et al., 2006). However, the behavioral profile resulting from this model and all 
other experimental stroke models are not well characterized and was the focus of the fourth 
study described here.  
In this study, both young adult and aged female rats were trained on a hippocampal de-
pendent memory task that has been well described and validated, namely, the 8-arm radial 
maze (Toumane et al., 1988). We found that aged female rats take longer to train and a higher 
percentage of them do not become trained in 50 sessions, compared to young adult rats. Fol-
lowing MCAO, however, no differences are found in working or reference memory between 
young adult and aged rats. We also measured no differences in sham-operated rats compared 
to age-matched MCAO rats, suggesting that our model of stroke does not affect hippocampal-
dependent memory. Despite our negative results, future studies to characterize the behavioral 
outcome from various models of experimental stroke would still hold an important relevance in 
the stroke field. As mentioned previously, behavioral outcome from stroke is far more important 
in the clinical setting than tissue volume lost.  
Future studies could improve on our data set by including additional behavioral assess-
ments, both those involving hippocampal-dependent memory as well as other cognitive tasks in 
order to more fully profile behavioral outcomes from experimental stroke in both young adult and 
aged rats. One specific study of interest, likely to demonstrate differences between young adult 
and aged rats, is the open-field test, which simply measures locomotor activity. Another poten-
tial candidate is gait analysis, which can be measured in great detail with new high-tech devic-
es. To more fully assess hippocampal-dependent memory, studies using the passive avoidance 
test and Morris water maze would be useful. In addition, histologic examination of the brain 
would provide invaluable information as to whether hippocampal neurons are affected by exper-
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imental stroke. Specific stains, such as Fluoro-Jade B, which labels degenerating neurons 
would allow visualization of hippocampal damage.  
Although the fibrin clot model is a clinically relevant model of stroke, a greater under-
standing of experimental stroke models would come from studies involving multiple models, 
both transient and permanent occlusion with both suture and fibrin clot. Also, an enhanced bat-
tery of behavioral tests should be explored in the acute and chronic phases of recovery as func-
tional outcome from stroke has the most clinical significance. In conclusion, accurate and mean-
ingful behavioral assessments of animals following experimental stroke are lacking, particularly 
ones that quantify observed differences between young adult and aged animal. Clinical rele-
vance of stroke research would be greatly enhanced by characterizing more fully the unique 
cognitive and behavioral outcomes in the various stroke models and utilizing those measures of 
most relevance in conjunction with infarct volume analysis.   
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